

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2010295497 B2

(54) Title
Immunological compositions for HIV

(51) International Patent Classification(s)
C07K 14/035 (2006.01) **C07K 19/00** (2006.01)
A61K 39/21 (2006.01)

(21) Application No: **2010295497** (22) Date of Filing: **2010.09.17**

(87) WIPO No: **WO11/035082**

(30) Priority Data

(31) Number (32) Date (33) Country
61/243,522 **2009.09.17** **US**

(43) Publication Date: **2011.03.24**
(44) Accepted Journal Date: **2014.10.09**

(71) Applicant(s)
Sanofi Pasteur, Inc.;The United States of America as represented by the Secretary of the Army, on behalf of Walter Reed Army Institute of Research;Ministry of Public Health;Global Solutions for Infectious Diseases

(72) Inventor(s)
Tartaglia, James T.;Gurunathan, Sanjay;Kim, Jerome H.;Francis, Don;Rerks-Ngarm, Supachai

(74) Agent / Attorney
Spruson & Ferguson, L 35 St Martins Tower 31 Market St, Sydney, NSW, 2000

(56) Related Art
WO 2001/054701 A1
GOMEZ-ROMAN V. R., et al, Journal of Acquired Immune Deficiency Syndromes, 2006, vol 43, no 3, pages 270-277
GOMEZ-ROMAN V. R., et al, The Journal of Immunology, 2005, vol 174, no 4, pages 2185-2189
PENG B., et al, Journal of Virology, 2005, vol 79, no 16, pages 10200-10209
BOGERS W. M. J. M., et al, "Systemic neutralising antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge", Virology, 2008, vol 382, no 2, pages 217-225
DOEPEL L. K: "Combination HIV vaccine induces diverse immune responses", NIH news release, 13 July 1999. Retrieved from internet: <http://www.nih.gov/news/pr/jul99/niaid-13.htm> [retrieved on 4 February 2013]
The AIDS Vaccine Evaluation Group 022 Protocol, The Journal of Infectious Diseases, 2001, vol 183, pages 563-570
BELSHE R. B., et al, The Journal of Infectious Diseases, 2001, vol 183, no 9, pages 1343-1352
JOHNSTON M. I., et al, "Progress in HIV vaccine development", Current Opinion in Pharmacology,

2001, vol 1, no 5, pages 504-510

RUSSELL N. D., et al, "Phase 2 study of an HIV-1 canarypox vaccine (vCP1452)

alone and in

combination with rgp120", **Journal of Acquired Immune Deficiency Syndromes**,

2007, vol 44, no 2, pages

203-212

THONGCHAROEN P., et al, "A phase 1/2 comparative vaccine trial of the safety and

immunogenicity of a CRF01_AE (subtype E) candidate vaccine", **Journal of Acquired Immune Deficiency**

Syndromes, 2007, vol 46, no 1, pages 48-55

RERKS-NGARM S., et al, "Phase III trial of HIV prime-boost vaccine combination in Thailand:

Follow up phase", **AIDS research and human retroviruses**, 2008, vol 24,

supplement 1, page 101

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 March 2011 (24.03.2011)(10) International Publication Number
WO 2011/035082 A1(51) International Patent Classification:
A61K 39/21 (2006.01) *C07K 19/00* (2006.01)
C07K 14/035 (2006.01)(21) International Application Number:
PCT/US2010/049206(22) International Filing Date:
17 September 2010 (17.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/243,522 17 September 2009 (17.09.2009) US(71) Applicants (for all designated States except US):
SANOFI PASTEUR, INC. [CA/CA]; One Discovery Drive, Swiftwater, PA 18370-9100 (US). THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE ARMY, on behalf of WALTER REED ARMY INSTITUTE OF RESEARCH [US/US]; 504 Scott Street, Frederick, MD 21702-5012 (US). GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES [US/US]; 830 Dubuque Avenue, South San Francisco, CA 94080 (US). MINISTRY OF PUBLIC HEALTH [TH/TH]; Tivanond Road, Nonthaburi, 11000 (TH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TARTAGLIA, James, T. [US/US]; Sanofi Pasteur, Inc., One Discovery Drive, Swiftwater, PA 18370-9100 (US). GURUNATHAN, Sanjay [US/US]; Sanofi Pasteur, Inc., One Discovery Drive, Swiftwater, PA 18370-9100 (US). KIM, Jerome, H. [US/US]; The U.s.a. As Represented

By The Secretary Of The, Army, On Behalf Of Walter Reed Army Inst., 504 Scott Street, Frederick, MD 21702-5012 (US). FRANCIS, Don [US/US]; Global Solutions For Infectious Diseases, 830 Dubuque Avenue, South San Francisco, CA 94080 (US). RERKS-NGARM, Supachai [TH/TH]; Ministry of Public Health, Tivanond Road, Nonthaburi, 11000 (TH).

(74) Agent: HALLORAN, Patrick, J.; 3141 Muirfield Road, Center Valley, PA 18034 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: IMMUNOLOGICAL COMPOSITIONS FOR HIV

FIGURE 3



(57) Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).

WO 2011/035082 A1



— *with sequence listing part of description (Rule 5.2(a))*

IMMUNOLOGICAL COMPOSITIONS FOR HIV

Related Applications

This application claims priority to U.S. Ser. No. 61/243,522 filed September 17, 2009.

5 Field of the Invention

The present invention relates generally to the field of immunology and, in particular to methods and compositions for immunizing and generating protection in a host against infection and disease with HIV.

10 Background of the Invention

Human immunodeficiency virus (HIV) is a human retrovirus and is the etiological agent of acquired immunodeficiency syndrome (AIDS). Despite the passage of more than 20 years since the discovery of HIV, no effective vaccine has been found to either ameliorate the disease or to prevent infection. By the end of the year 2007, more than 30 million people worldwide 15 were infected with HIV, with more than 20 million of those people living in sub-Saharan Africa (Report on the Global AIDS Epidemic, Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008).

A hallmark of resistance to future viral infection is the generation of 'neutralizing antibodies' capable of recognizing the viral pathogen. Another measure is cellular immunity 20 against infected cells. In typical viral infections, generation of neutralizing antibodies and cellular immunity heralds recovery from infection. In HIV-1 infection, however, neutralizing antibodies and cellular immunity appear very early during the infection and have been associated with only a transient decrease in viral burden. In spite of the generation of neutralizing antibodies and cellular immunity, viral replication in HIV-1 infection rebounds and AIDS (acquired immune deficiency 25 syndrome) develops. Thus, in HIV-1 infection, neutralizing antibodies and cellular immunity are not accurate measures of protective immunity. Protective immunity, meaning the vaccinees are protected against new infections by HIV, is a major unaccomplished goal of those skilled in the art.

Several potential vaccines have been tested in humans but found not to be protective. For 30 examples, polypeptide vaccines based on gp120 have been tested (e.g., AIDSVAX® B/B, AIDSVAX® B/E (Vaxgen)) as solo vaccines or together in a prime-boost format, but have not

shown protection against HIV infection (McCarthy, M. *Lancet.* 362(9397):1728 (2003); Nitayaphan, et al. *J. Inf. Dis.* 190:702-6 (2004); Pitisuttithum, P. 11th Conf. Retr. Opp. Inf. 2004, 115: Abstract 107). Many studies have also been performed using animal models (e.g., monkeys). However, while primate data are instructive they also highlight the gaps in our 5 understanding of immunological mechanism that mediate vaccine associated protection and emphasize the need to conduct human efficacy studies to test promising candidate vaccines empirically.

ALVAC-HIV (vCP1521) vaccine is a preparation of recombinant canarypox-derived virus expressing the products of the HIV-1 *env* and *gag* genes. The genes are inserted into the 10 C6 locus under the control of the vaccinia virus H6 and I3L promoters respectively. The gp120 *env* sequence is derived from the HIV-92TH023 (subtype E) strain, but the anchoring part of gp41 is derived from the HIV-LAI (subtype B) strain. ALVAC-HIV infected cells present *env* and *gag* proteins in a near-native conformation (Fang, et al. *J. Infect. Dis.* 180 (4): 1122-32 (1999)). In addition, intracellular processing of the HIV-1 proteins via the MHC class I pathway 15 facilitates stimulation of cytotoxic T-lymphocytes. Part of the rationale for use of Gag from a subtype B in Thailand is that portions of the *gag* gene are conserved among virus subtypes. Therefore, *gag*-specific CTL elicited by vCP1521 may cross-react with CTL epitopes on non-subtype B primary viruses. Data from an AVEG-sponsored prime-boost trial (vCP205 alone or boosted with Chiron SF2 gp120/MF59) showed that CD8⁺ CTL from some vaccine recipients 20 recognized target cells infected with non-subtype B viruses, including subtype E (Ferrari, et al. *Proc. Natl. Acad. Sci. USA*, 94:1396-401 (1997)).

In view of this data, several attempts have been made to provide protection using a prime-boost immunization format (McNeil, et al. *Science.* 303:961 (2004)). For example, AIDSVAX[®] B/E (VaxGen) and ALVAC-HIV have been used as the prime and boost compositions, 25 respectively, and shown to induce neutralizing antibodies (Karnasuta, et al. *Vaccine*, 23: 2522-2529 (2005)). In one safety trial, neutralizing antibodies were observed in 84% to 100% of subjects, cytotoxic lymphocytes (CTL) were observed in 16-25% of subjects, and lympho-proliferation was observed in 55-93% of subjects. In another safety trial, neutralizing antibodies 30 were observed in 31% to 71% of subjects, cytotoxic lymphocytes (CTL) were observed in about 25% of subjects, and lympho-proliferation was observed in 58-71% of subjects. However, protection against infection by HIV was not shown, leading some to question the value of such a

combination vaccine (Burton, et al. *Science*. 303; 316 (2004); Letters to the Editor. *Science*. 305:177-180 (2004)).

To date, no vaccine has shown protection against HIV infection. Thus, there is a clear need in the art for compositions and methods for protectively immunizing humans against HIV. Such compositions and methods are provided by this disclosure.

Brief Description of the Drawings

Figure 1. Comparison of the predicted amino acid sequence for A244 rgp120/HIV-1 protein (gd244) with the predicted sequence for MN rgp120/HIV-1 protein (MN.mature).

Figure 2. A. Map of ALVAC-HIV (vCP1521) genome. B. Nucleotide sequence of the HIV insert contained within ALVAC-HIV (vCP1521).

Figure 3. Efficacy of the AIDSVAX® B/E / ALVAC-HIV prime-boost vaccine.

Summary of the Invention

5 According to a first aspect of the present invention, there is provided a method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being:

a first composition comprising multiple doses of an avipox vector encoding at least a portion of HIV gp120 and, subsequently,

10 a second composition comprising multiple doses of a polypeptide corresponding to at least a portion of HIV gp120,

to a population of human beings that induces a protective immune response against infection by HIV in at least about one-third of the population, wherein:

15 a) one or more doses of the first composition is administered repeatedly to the population as the sole active agent; and,

b) one or more doses of the second composition is subsequently administered to the population as the sole active agent or in combination with one or more doses of the first composition.

According to a second aspect of the present invention, there is provided a kit when used to induce a protective immune response against infection by HIV in at least about one-third of the population, said kit comprising a first composition comprising multiple doses of an avipox vector encoding HIV gp120 and a second composition comprising multiple doses of a polypeptide corresponding to at least a portion of HIV gp120, and instructions for repeatedly administering one or more doses of the first composition to a human being and subsequently administering one or more doses of the second composition or the first and second compositions to the human being.

The reagents and methodologies described herein may be used to protectively immunize a human being against human immunodeficiency virus, which has not been previously demonstrated. In one embodiment, a two-part composition including a first composition comprising an expression vector encoding an HIV immunogen, and a second composition comprising a polypeptide derived from or representing an HIV immunogen is provided. As shown herein, administration of the first composition prior to the second composition, and then administering the first and second compositions, protects human beings against infection by HIV. In an exemplary embodiment, the first composition includes a live, attenuated viral vector encoding at least one HIV immunogen, and the second composition includes an HIV immunogen in the form of a polypeptide. In certain embodiments, a method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being a vaccine composition. The composition consists essentially of a first composition and a second composition, the first composition consisting essentially of a live, attenuated avipox (e.g., canarypox, ALVAC) vector encoding multiple HIV immunogens, and the second

composition including one or more polypeptides corresponding in amino acid sequence to at least a portion of HIV gp120. In some embodiments, at least one of the compositions comprises an amino acid sequence corresponding to that of HIV and at least one amino acid sequence corresponding to a herpes simplex virus (HSV). In some embodiments, the 5 first composition is administered to the human being and the first and second compositions are subsequently administered to the human being. In certain embodiments, the compositions are administered via the intramuscular route. Using this method, it has been found for the first time that human beings may be protected from infection by HIV. In certain embodiments, the method involves administering the vaccine to a population of 10 human beings and at least about one-third of that population is protected from infection by HIV.

Detailed Description

The present invention provides compositions and methodologies useful for 15 treating and / or preventing conditions relating to an infectious or other agent(s) such as a tumor cell by stimulating an immune response against such an agent. In general, the immune response results from expression of an immunogen derived from or related to such an agent following administration of a nucleic acid vector encoding the immunogen, for example. In certain embodiments, multiple immunogens (which may be the same or 20 different) are utilized. In other embodiments, variants or derivatives (i.e., by substitution, deletion or addition of amino acids or nucleotides encoding the same) of an immunogen or immunogens (which may be the same or different) may be utilized.

An immunogen may be a moiety (e.g., polypeptide, peptide or nucleic acid) that induces or enhances the immune response of a host to whom or to which the immunogen 25 is administered. An immune response may be induced or enhanced by either increasing or decreasing the frequency, amount, or half-life of a particular immune modulator (e.g., the expression of a cytokine, chemokine, co-stimulatory molecule). This may be directly observed within a host cell containing a polynucleotide of interest (e.g., following infection by a recombinant virus) or within a nearby cell or tissue (e.g., indirectly). The 30 immune response is typically directed against a target antigen. For example, an immune response may result from expression of an immunogen in a host following administration

of a nucleic acid vector encoding the immunogen to the host. The immune response may result in one or more of an effect (e.g., maturation, proliferation, direct- or cross-presentation of antigen, gene expression profile) on cells of either the innate or adaptive immune system. For example, the immune response may involve, effect, or be detected 5 in innate immune cells such as, for example, dendritic cells, monocytes, macrophages, natural killer cells, and / or granulocytes (e.g., neutrophils, basophils or eosinophils). The immune response may also involve, effect, or be detected in adaptive immune cells including, for example, lymphocytes (e.g., T cells and / or B cells). The immune response may be observed by detecting such involvement or effects including, for 10 example, the presence, absence, or altered (e.g., increased or decreased) expression or activity of one or more immunomodulators such as a hormone, cytokine, interleukin (e.g., any of IL-1 through IL-35), interferon (e.g., any of IFN-I (IFN- α , IFN- β , IFN- ϵ , IFN- κ , IFN- τ , IFN- ζ , IFN- ω), IFN-II (e.g., IFN- γ), IFN-III (IFN- λ 1, IFN- λ 2, IFN- λ 3)), 15 chemokine (e.g., any CC cytokine (e.g., any of CCL1 through CCL28), any CXC chemokine (e.g., any of CXCL1 through CXCL24), Mip1 α), any C chemokine (e.g., XCL1, XCL2), any CX3C chemokine (e.g., CX3CL1)), tumor necrosis factor (e.g., TNF- α , TNF- β), negative regulators (e.g., PD-1, IL-T) and / or any of the cellular components (e.g., kinases, lipases, nucleases, transcription-related factors (e.g., IRF-1, IRF-7, STAT-5, NFKB, STAT3, STAT1, IRF-10), and / or cell surface markers suppressed or induced 20 by such immunomodulators) involved in the expression of such immunomodulators. The presence, absence or altered expression may be detected within cells of interest or near those cells (e.g., within a cell culture supernatant, nearby cell or tissue *in vitro* or *in vivo*, and / or in blood or plasma). Administration of the immunogen may induce (e.g., stimulate a *de novo* or previously undetected response), or enhance or suppress an 25 existing response against the immunogen by, for example, causing an increased antibody response (e.g., amount of antibody, increased affinity / avidity) or an increased cellular response (e.g., increased number of activated T cells, increased affinity / avidity of T cell receptors, cytotoxicity including but not limited to antibody-dependnet cellular cytotoxicity (ADCC), proliferation). In the case of HIV infections, no clear correlates of immunity 30 have been associated with immunity (especially protective immunity), but any of the measures described herein may be helpful in determining the usefulness of the

compositions and methods described herein. Some immune responses may, in the case of a viral immunogen, lead to decreased viral load in, or lead to elimination of the virus from, a host. In certain embodiments, the immune response may be protective, meaning that the immune response may be capable of preventing initiation or continued infection of or growth within a host and / or by eliminating an agent (e.g., a causative agent, such as HIV) from the host. In some instances, elimination of an agent from the host may mean that the vaccine is therapeutic. In some embodiments, a composition comprising an immunogen may be administered to a population of hosts (e.g., human beings) and determined to provide protective immunity to only a portion of that population. The 5 composition may therefore be considered to protect a portion of that population (e.g., about 1/10, 1/4, 1/3, 1/2, or 3/4 of the population). The proportion of the population that is protected may be calculated and thereby provide the efficacy of the composition in that 10 population (e.g., about 10%, 25%, 33%, 50%, or 75% efficacy).

With respect to HIV, immunogens may be selected from any HIV isolate (e.g., 15 any primary or cultured HIV-1, HIV-2, and / or HIV-3 isolate, strain, or clade). As is well-known in the art, HIV isolates are now classified into discrete genetic subtypes. HIV-1 is known to comprise at least ten subtypes (A1, A2, A3, A4, B, C, D, E, F1, F2, G, H, J and K) (Taylor et al, NEJM, 359(18):1965-1966 (2008)). HIV-2 is known to include 20 at least five subtypes (A, B, C, D, and E). Subtype B has been associated with the HIV epidemic in homosexual men and intravenous drug users worldwide. Most HIV-1 immunogens, laboratory adapted isolates, reagents and mapped epitopes belong to subtype B. In sub-Saharan Africa, India, and China, areas where the incidence of new HIV infections is high, HIV-1 subtype B accounts for only a small minority of infections, and subtype HIV-1 C appears to be the most common infecting subtype. Thus, in certain 25 embodiments, it may be preferable to select immunogens from particular subtypes (e.g., HIV-1 subtypes B and / or C). It may be desirable to include immunogens from multiple HIV subtypes (e.g., HIV-1 subtypes B and C, HIV-2 subtypes A and B, or a combination of HIV-1, HIV-2, and/or HIV-3 subtypes) in a single immunological composition. Suitable HIV immunogens include HIV envelope (env; e.g., NCBI Ref. Seq. NP_057856, 30 or as shown in any of Figs. 1, 2 and / or SEQ ID NOS. 1-6), gag (e.g., p6, p7, p17, p24, GenBank AAD39400.1), the protease encoded by *pol* (e.g., UniProt P03366), nef (e.g.,

GenBank CAA41585.1; Shugars, et al. J. Virol. Aug. 1993, pp. 4639-4650 (1993)), as well as variants, derivatives, and fusion proteins thereof, as described by, for example, Gomez et al. Vaccine, Vol. 25, pp. 1969-1992 (2007). Immunogens (e.g., env and pol) may be combined as desired. Immunogens from different HIV isolates (e.g., HIV-1 A1 5 env and HIV-1 A2 env) may also be combined (e.g., AIDSVAX B/BTM and AIDSVAXTM B/E). In some embodiments, at least one of the compositions comprises an amino acid sequence corresponding to that of HIV and at least one amino acid sequence corresponding to a herpes simplex virus (HSV). In some embodiments, the HSV antigen may be the glycoprotein D (gD) leader sequence shown in **Fig. 1**. In certain 10 embodiments, the HSV amino acid sequence comprises KYALADASLKMADPNRFRGKDLPVLDQL (SEQ ID NO. 7), or a fragment or derivative thereof. In some embodiments, at least one of the compositions comprises SEQ ID NO. 7. In some embodiments, a suitable immunogen may be the polypeptide gd244 as shown in **Fig. 1**, or a fragment thereof. In others, a suitable immunogen may be 15 the polypeptide "MN.mature" shown in **Fig. 1**, or a fragment thereof. Suitable strains and combinations may be selected by the skilled artisan as desired.

In some embodiments, a method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being at least one dose of a first composition comprising a viral vector encoding an HIV 20 polypeptide or fragment or derivative thereof and subsequently administering to the human being at least one dose of a second composition comprising the HIV polypeptide or fragment or derivative thereof, wherein a protective immune response directed against HIV results, is provided. In some embodiments, a method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the 25 human being a vaccine consisting essentially of a first composition and a second composition, the first composition consisting essentially of a live, attenuated viral vector encoding at least one HIV gp120 or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof, the second composition consisting essentially of at least one HIV gp120 polypeptide or fragment or derivative thereof and, optionally, at least one additional HIV polypeptide or fragment or derivative thereof; the method comprising the steps of administering the first composition 30

to the human being and subsequently administering to the human being at least one composition or combination of compositions selected from the group consisting of: the second composition alone; the first and second compositions, optionally separately or together as a single dose; at least one additional dose of the first composition followed by 5 at least one dose of the second composition; the second composition followed by at least one additional dose of the first composition, optionally followed by at least one additional dose of the first and / or second composition; wherein a protective immune response against HIV is induced in the human being, is provided. In some embodiments, the compositions are administered together (e.g., at essentially the same time (e.g., 10 simultaneously) to the same or different sites of a host) or separately (e.g., either in time or site of administration in the host).

In certain embodiments, at least one of the compositions comprises an amino acid sequence corresponding to that of a herpes simplex virus (HSV) (e.g., glycoprotein D (gD) leader sequence shown in **Fig. 1**). In certain embodiments, the HSV amino acid 15 sequence may include, for example, KYALADASLKMADPNRFRGKDLPVLDQL (SEQ ID NO. 7), or a fragment thereof. In some embodiments, the HSV amino acid sequence may be that shown in the polypeptide "MN.mature" shown in **Fig. 1** (SEQ ID NO. 3), or a fragment thereof. In some embodiments, the HSV amino acid sequence may be that shown in the polypeptide gd244 as shown in **Fig. 1** (SEQ ID NO. 4), or a 20 fragment thereof. In some embodiments, the gp120 amino acid sequence may be SEQ ID NO. 5. In some embodiments, at least one of the compositions may comprise a polypeptide of any one or more of SEQ ID NOS. 3, 4, 5, or 7. By "comprise a polypeptide" is meant both a polypeptide per se and / or one encoded by a nucleic acid contained within an expression vector. Variations and derivatives of the polypeptides 25 referred to herein may also be suitable, as could be determined by one of skill in the art.

In some embodiments, the first composition is administered repeatedly prior to at least one administration of the second composition, where the time between administrations is of sufficient length to allow for the development of an immune response within the human being. In some embodiments, the methods described herein 30 comprise administering the vaccine is administered to a population of human beings such that at least about one-third of that population is protected from infection by HIV. In

some embodiments, the first composition is administered repeatedly prior to at least one administration of the second composition, with the time between administrations is of sufficient length to allow for the development of an immune response within the human being. In certain embodiments, administration of either or both the first and second compositions is via a route selected from the group consisting of mucosal, intradermal, intramuscular, subcutaneous, via skin scarification, intranodal, or intratumoral. The dose of the compositions may vary, but in some embodiments, the amount of viral vector administered in each dose is the equivalent of about 10^7 CCID₅₀ and the total amount of polypeptide administered in each dose is about 600 μ g. In some embodiments, the viral vector may be a poxviral vector such as vaccinia, NYVAC, Modified Virus Ankara (MVA), avipox, canarypox, ALVAC, ALVAC(2), fowlpox, or TROVAC. In some embodiments, the viral vector may be ALVAC-HIV (vCP1521). The viral vector may comprise the nucleic acid sequence of SEQ ID NO. 1 or 5, for example. The second composition may be AIDSVAX® B/B or AIDSVAX® B/E. In some embodiments, the viral vector may be ALVAC-HIV (vCP1521) and the second composition may be AIDSVAX® B/E.

In certain embodiments, the HIV polypeptide or HIV gp120 is derived from an HIV virus selected from the group consisting of HIV-1, HIV-2, and HIV-3, wherein the first and second composition contain the same or different HIV polypeptides and / or gp120. The HIV-1 may be, for example, HIV-1 subtype A1, HIV-1 subtype A2, HIV-1 subtype A3, HIV-1 subtype A4, HIV-1 subtype B, HIV-1 subtype C, HIV-1 subtype D, HIV-1 subtype E, HIV-1 subtype F1, HIV-1 subtype F2, HIV-1 subtype G, HIV-1 subtype H, HIV-1 subtype J and HIV-1 subtype K. The HIV-2 may be, for example, HIV-2 subtype A, HIV-2 subtype B, HIV-2 subtype C, HIV-2 subtype D, and HIV-2 subtype E. The viral vector may encode, for example, at least one polypeptide selected from the group consisting of HIV gp120 MN 12-485, HIV gp120 A244 12-484, and HIV gp120 GNE8 12-477.

Where multiple HIV immunogens are used, the at least one additional HIV immunogen may be, for example, gag, pol, nef, a variant thereof, and a derivative thereof. Thus, in some embodiments, the first or second composition additionally contain

at least one additional HIV immunogen selected from the group consisting of gag, the protease component encoded by pol, nef, a variant thereof, and a derivative thereof.

In preferred embodiments of the present invention, vectors are used to transfer a nucleic acid sequence encoding a polypeptide to a cell. A vector is any molecule used to transfer a nucleic acid sequence to a host cell. In certain cases, an expression vector is utilized. An expression vector is a nucleic acid molecule that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and / or control the expression of the transferred nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and splicing, if introns are present. Expression vectors typically comprise one or more flanking sequences operably linked to a heterologous nucleic acid sequence encoding a polypeptide. As used herein, the term operably linked refers to a linkage between polynucleotide elements in a functional relationship such as one in which a promoter or enhancer affects transcription of a coding sequence. Flanking sequences may be homologous (i.e., from the same species and / or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), or synthetic, for example.

In certain embodiments, it is preferred that the flanking sequence is a transcriptional regulatory region that drives high-level gene expression in the target cell. The transcriptional regulatory region may comprise, for example, a promoter, enhancer, silencer, repressor element, or combinations thereof. The transcriptional regulatory region may be either constitutive, tissue-specific, cell-type specific (i.e., the region is drives higher levels of transcription in a one type of tissue or cell as compared to another), or regulatable (i.e., responsive to interaction with a compound such as tetracycline). The source of a transcriptional regulatory region may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence functions in a cell by causing transcription of a nucleic acid within that cell. A wide variety of transcriptional regulatory regions may be utilized in practicing the present invention.

In some embodiments, derivatives of polypeptides, peptides, or polynucleotides incorporated into or expressed by the vectors described herein including, for example,

fragments and / or variants thereof may be utilized. Derivatives may result from, for example, substitution, deletion, or addition of amino acids or nucleotides from or to the reference sequence (e.g., the parental sequence). A derivative of a polypeptide or protein, for example, typically refers to an amino acid sequence that is altered with respect to the referenced polypeptide or peptide. A derivative of a polypeptide typically retains at least one activity of the polypeptide. A derivative will typically share at least approximately 60%, 70%, 80%, 90%, 95%, or 99% identity to the reference sequence. With respect to polypeptides and peptides, the derivative may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties. A derivative may 10 also have "nonconservative" changes. Exemplary, suitable conservative amino acid substitutions may include, for example, those shown in **Table 1**:

Table 1

Original Residues	Exemplary Substitutions	Preferred Substitutions
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln	Gln
Asp	Glu	Glu
Cys	Ser, Ala	Ser
Gln	Asn	Asn
Glu	Asp	Asp
Gly	Pro, Ala	Ala
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleucine	Leu
Leu	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, 1,4 Diamino-butyric Acid, Gln, Asn	Arg
Met	Leu, Phe, Ile	Leu
Phe	Leu, Val, Ile, Ala, Tyr	Leu
Pro	Ala	Gly
Ser	Thr, Ala, Cys	Thr
Thr	Ser	Ser
Trp	Tyr, Phe	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

Other amino acid substitutions may be considered non-conservative. Derivatives may 15 also include amino acid or nucleotide deletions and / or additions / insertions, or some combination of these. Guidance in determining which amino acid residues or nucleotides

may be substituted, inserted, or deleted without abolishing the desired activity of the derivative may be identified using any of the methods available to one of skill in the art.

Derivatives may also refer to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide may include, for example, 5 replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide may encode a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide may be one modified by glycosylation, pegylation, biotinylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was 10 derived.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative 15 amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide. Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for 20 example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length 25 over which percentage identity may be measured. Percent identity can be measured both globally or locally. Examples of alignment algorithms known in the art for global alignments are ones which attempt to align every residue in every sequence, such as the Needleman-Wunsch algorithm. Local alignment algorithms are useful for dissimilar sequences that contain regions of similar sequence motifs within their larger sequence, 30 such as the Smith-Waterman algorithm.

As mentioned above, this disclosure relates to compositions comprising recombinant vectors, the vectors per se, and methods of using the same. A "vector" is any moiety (e.g., a virus or plasmid) used to carry, introduce, or transfer a polynucleotide or interest to another moiety (e.g., a host cell). In certain cases, an expression vector is 5 utilized. An expression vector is a nucleic acid molecule containing a polynucleotide of interest encoding a polypeptide, peptide, or polynucleotide and also containing other polynucleotides that direct and / or control the expression of the polynucleotide of interest. Expression includes, but is not limited to, processes such as transcription, translation, and / or splicing (e.g., where introns are present).

10 Viral vectors that may be used include, for example, retrovirus, adenovirus, adeno-associated virus (AAV), alphavirus, herpes virus, and poxvirus vectors, among others. Many such viral vectors are available in the art. The vectors described herein may be constructed using standard recombinant techniques widely available to one skilled in the art. Such techniques may be found in common molecular biology references such as 15 *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991, Academic Press, San Diego, CA), and *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990, Academic Press, San Diego, CA).

20 Suitable retroviral vectors may include derivatives of lentivirus as well as derivatives of murine or avian retroviruses. Exemplary, suitable retroviral vectors may include, for example, Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), SIV, BIV, HIV and Rous Sarcoma Virus (RSV). A number of retroviral vectors can incorporate multiple exogenous polynucleotides. As recombinant retroviruses are defective, they require 25 assistance in order to produce infectious vector particles. This assistance can be provided by, for example, helper cell lines encoding retrovirus structural genes. Suitable helper cell lines include Ψ 2, PA317 and PA12, among others. The vector virions produced using such cell lines may then be used to infect a tissue cell line, such as NIH 3T3 cells, to produce large quantities of chimeric retroviral virions. Retroviral vectors may be 30 administered by traditional methods (i.e., injection) or by implantation of a "producer cell line" in proximity to the target cell population (Culver, K., et al., 1994, *Hum. Gene Ther.*,

5 (3): 343-79; Culver, K., *et al.*, *Cold Spring Harb. Symp. Quant. Biol.*, 59: 685-90); Oldfield, E., 1993, *Hum. Gene Ther.*, 4 (1): 39-69). The producer cell line is engineered to produce a viral vector and releases viral particles in the vicinity of the target cell. A portion of the released viral particles contact the target cells and infect those cells, thus 5 delivering a nucleic acid encoding an immunogen to the target cell. Following infection of the target cell, expression of the polynucleotide of interest from the vector occurs.

Adenoviral vectors have proven especially useful for gene transfer into eukaryotic cells (Rosenfeld, M., *et al.*, 1991, *Science*, 252 (5004): 431-4; Crystal, R., *et al.*, 1994, *Nat. Genet.*, 8 (1): 42-51), the study eukaryotic gene expression (Levrero, M., *et al.*, 10 1991, *Gene*, 101 (2): 195-202), vaccine development (Graham, F. and Prevec, L., 1992, *Biotechnology*, 20: 363-90), and in animal models (Stratford-Perricaudet, L., *et al.*, 1992, *Bone Marrow Transplant.*, 9 (Suppl. 1): 151-2 ; Rich, *et al.*, 1993, *Hum. Gene Ther.*, 4 (4): 461-76). Experimental routes for administrating recombinant Ad to different tissues *in vivo* have included intratracheal instillation (Rosenfeld, M., *et al.*, 1992, *Cell*, 68 (1): 15 143-55) injection into muscle (Quantin, B., *et al.*, 1992, *Proc. Natl. Acad. Sci. U.S.A.*, 89 (7): 2581-4), peripheral intravenous injection (Herz, J., and Gerard, R., 1993, *Proc. Natl. Acad. Sci. U.S.A.*, 90 (7): 2812-6) and / or stereotactic inoculation to brain (Le Gal La Salle, G., *et al.*, 1993, *Science*, 259 (5097): 988-90), among others.

Adeno-associated virus (AAV) demonstrates high-level infectivity, broad host 20 range and specificity in integrating into the host cell genome (Hermonat, P., *et al.*, 1984, *Proc. Natl. Acad. Sci. U.S.A.*, 81 (20): 6466-70). And Herpes Simplex Virus type-1 (HSV-1) is yet another attractive vector system, especially for use in the nervous system because of its neurotropic property (Geller, A., *et al.*, 1991, *Trends Neurosci.*, 14 (10): 428-32; Glorioso, *et al.*, 1995, *Mol. Biotechnol.*, 4 (1): 87-99; Glorioso, *et al.*, 1995, 25 *Annu. Rev. Microbiol.*, 49: 675-710).

Alphavirus may also be used to express the immunogen in a host. Suitable members of the Alphavirus genus include, among others, Sindbis virus, Semliki Forest virus (SFV), the Ross River virus and Venezuelan, Western and Eastern equine encephalitis viruses, among others. Expression systems utilizing alphavirus vectors are 30 described in, for example, U.S. Pat. Nos. 5,091,309; 5,217,879; 5,739,026; 5,766,602; 5,843,723; 6,015,694; 6,156,558; 6,190,666; 6,242,259; and, 6,329,201; WO 92/10578;

Xiong et al., *Science*, Vol 243, 1989, 1188-1191; Liljestrom, et al. *Bio/Technology*, 9: 1356-1361, 1991. Thus, the use of alphavirus as an expression system is well known by those of skill in the art.

Poxvirus is another useful expression vector (Smith, et al. 1983, *Gene*, 25 (1): 21-8; Moss, et al, 1992, *Biotechnology*, 20: 345-62; Moss, et al, 1992, *Curr. Top. Microbiol. Immunol.*, 158: 25-38; Moss, et al. 1991. *Science*, 252: 1662-1667). The most often utilized poxviral vectors include vaccinia and derivatives therefrom such as NYVAC and MVA, and members of the avipox genera such as fowlpox, canarypox, ALVAC, and ALVAC(2), among others.

An exemplary suitable vector is NYVAC (vP866) which was derived from the Copenhagen vaccine strain of vaccinia virus by deleting six nonessential regions of the genome encoding known or potential virulence factors (see, for example, U.S. Pat. Nos. 5,364,773 and 5,494,807). The deletion loci were also engineered as recipient loci for the insertion of foreign genes. The deleted regions are: thymidine kinase gene (TK; J2R); hemorrhagic region (u; B13R+B14R); A type inclusion body region (ATI; A26L); hemagglutinin gene (HA; A56R); host range gene region (C7L-K1L); and, large subunit, ribonucleotide reductase (I4L). NYVAC is a genetically engineered vaccinia virus strain that was generated by the specific deletion of eighteen open reading frames encoding gene products associated with virulence and host range. NYVAC has been shown to be useful for expressing TAs (see, for example, U.S. Pat. No. 6,265,189). NYVAC (vP866), vP994, vCP205, vCP1433, placZH6H4Lreverse, pMPC6H6K3E3 and pC3H6FHVB were also deposited with the ATCC under the terms of the Budapest Treaty, accession numbers VR-2559, VR-2558, VR-2557, VR-2556, ATCC-97913, ATCC-97912, and ATCC-97914, respectively.

Another suitable virus is the Modified Vaccinia Ankara (MVA) virus which was generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of vaccinia virus (CVA) (for review, see Mayr, A., et al. *Infection* 3, 6-14 (1975)). It was shown in a variety of animal models that the resulting MVA was significantly avirulent (Mayr, A. & Danner, K. (1978) *Dev. Biol. Stand.* 41: 225,34) and has been tested in clinical trials as a smallpox vaccine (Mayr et al., *Zbl. Bakt. Hyg. I, Abt. Org. B* 167, 375-390 (1987), Stickl et al., *Dtsch. med. Wschr.* 99, 2386-2392 (1974)). MVA has also been

engineered for use as a viral vector for both recombinant gene expression studies and as a recombinant vaccine (Sutter, G. *et al.* (1994), *Vaccine* 12: 1032-40; Blanchard *et al.*, 1998, *J Gen Virol* 79, 1159-1167; Carroll & Moss, 1997, *Virology* 238, 198-211; Altenberger, U.S. Pat. No. 5,185,146; Ambrosini *et al.*, 1999, *J Neurosci Res* 55(5), 569).

5 Modified virus Ankara (MVA) has been previously described in, for example, U.S. Pat. Nos. 5,185,146 and 6,440,422; Sutter, et al. (*B. Dev. Biol. Stand. Basel, Karger* 84:195-200 (1995)); Antoine, et al. (*Virology* 244: 365-396, 1998); Sutter et al. (*Proc. Natl. Acad. Sci. USA* 89: 10847-10851, 1992); Meyer et al. (*J. Gen. Virol.* 72: 1031-1038, 1991); Mahnel, et al. (*Berlin Munch. Tierarztl. Wochenschr.* 107: 253-256, 1994); Mayr et al. (*Zbl. Bakt. Hyg. I, Abt. Org. B* 167: 375-390 (1987); and, Stickl et al. (*Dtsch. med. Wschr.* 99: 2386-2392 (1974)). An exemplary MVA is available from the ATCC under accession numbers VR-1508 and VR-1566.

10 ALVAC-based recombinant viruses (i.e., ALVAC-1 and ALVAC-2) are also suitable for use in practicing the present invention (see, for example, U.S. Pat. No. 5,756,103). ALVAC(2) is identical to ALVAC(1) except that ALVAC(2) genome comprises the vaccinia E3L and K3L genes under the control of vaccinia promoters (U.S. Pat. No. 6,130,066; Beattie et al., 1995a, 1995b, 1991; Chang et al., 1992; Davies et al., 1993). Both ALVAC(1) and ALVAC(2) have been demonstrated to be useful in expressing foreign DNA sequences, such as TAs (Tartaglia et al., 1993 a,b; U.S. Pat. No. 5,833,975). ALVAC was deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, USA, ATCC accession number VR-2547. Vaccinia virus host range genes (e.g., C18L, C17L, C7L, K1L, E3L, B4R, B23R, and B24R) have also been shown to be expressible in canarypox (e.g., U.S. Pat. No. 7,473,536).

15 Another useful poxvirus vector is TROVAC. TROVAC refers to an attenuated fowlpox that was a plaque-cloned isolate derived from the FP-1 vaccine strain of fowlpoxvirus which is licensed for vaccination of 1 day old chicks. TROVAC was likewise deposited under the terms of the Budapest Treaty with the ATCC, accession number 2553.

20 "Non-viral" plasmid vectors may also be suitable for use. Plasmid DNA molecules comprising expression cassettes for expressing an immunogen may be used for

“naked DNA” immunization. Preferred plasmid vectors are compatible with bacterial, insect, and / or mammalian host cells. Such vectors include, for example, PCR-II, pCR3, and pcDNA3.1 (Invitrogen, San Diego, CA), pBSII (Stratagene, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlueBacII, Invitrogen), pDSR-alpha (PCT pub. No. WO 90/14363) and pFastBacDual (Gibco-BRL, Grand Island, NY) as well as Bluescript[®] plasmid derivatives (a high copy number COLE1-based phagemid, Stratagene Cloning Systems, La Jolla, CA), PCR cloning plasmids designed for cloning Taq-amplified PCR products (e.g., TOPOTM TA cloning[®] kit, PCR2.1[®] plasmid derivatives, Invitrogen, Carlsbad, CA).

Bacterial vectors may also be suitable for use. These vectors include, for example, *Shigella*, *Salmonella* (e.g., Darji, et al. *Cell*, 91: 765-775 (1997); Woo, et al. *Vaccine*, 19: 2945-2954 (2001)), *Vibrio cholerae*, *Lactobacillus*, *Bacille calmette guérin* (BCG), and *Streptococcus* (e.g., WO 88/6626, WO 90/0594, WO 91/13157, WO 92/1796, and WO 92/21376). Many other non-viral plasmid expression vectors and systems are known in the art and could be used with the current invention.

Nucleic acid delivery or transformation techniques that may be used include DNA-ligand complexes, adenovirus-ligand-DNA complexes, direct injection of DNA, CaPO₄ precipitation, gene gun techniques, electroporation, and colloidal dispersion systems, among others. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome, which are artificial membrane vesicles useful as delivery vehicles *in vitro* and *in vivo*. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, R., et al. *Trends Biochem. Sci.*, 6: 77 (1981)). The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Examples of lipids useful in liposome production include phosphatidyl compounds, such as

phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include
5 egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

Strategies for improving the efficiency of nucleic acid-based immunization may also be used including, for example, the use of self-replicating viral replicons (Caley, et al. *Vaccine*, 17: 3124-2135 (1999); Dubensky, et al. *Mol. Med.* 6: 723-732 (2000);
10 Leitner, et al. *Cancer Res.* 60: 51-55 (2000)), codon optimization (Liu, et al. *Mol. Ther.*, 1: 497-500 (2000); Dubensky, *supra*; Huang, et al. *J. Virol.* 75: 4947-4951 (2001)), in vivo electroporation (Widera, et al. *J. Immunol.* 164: 4635-3640 (2000)), incorporation of CpG stimulatory motifs (Gurunathan, et al. *Ann. Rev. Immunol.* 18: 927-974 (2000); Leitner, *supra*), sequences for targeting of the endocytic or ubiquitin-processing pathways
15 (Thomson, et al. *J. Virol.* 72: 2246-2252 (1998); Velders, et al. *J. Immunol.* 166: 5366-5373 (2001)), and / or prime-boost regimens (Gurunathan, *supra*; Sullivan, et al. *Nature*, 408: 605-609 (2000); Hanke, et al. *Vaccine*, 16: 439-445 (1998); Amara, et al. *Science*, 292: 69-74 (2001)). Other methods are known in the art, some of which are described below.

20 In other embodiments, it may be advantageous to combine or include within the compositions or recombinant vectors additional polypeptides, peptides or polynucleotides encoding one or more polypeptides or peptides that function as "co-stimulatory" component(s). Such co-stimulatory components may include, for example, cell surface proteins, cytokines or chemokines in a composition of the present invention. The co-stimulatory component may be included in the composition as a polypeptide or peptide, or as a polynucleotide encoding the polypeptide or peptide, for example. Suitable co-stimulatory molecules include, for instance, polypeptides that bind members of the CD28 family (i.e., CD28, ICOS; Hutloff, et al. *Nature* 1999, 397: 263-265; Peach, et al. *J. Exp. Med.* 1994, 180: 2049-2058) such as the CD28 binding polypeptides B7.1 (CD80; Schwartz, 1992; Chen et al, 1992; Ellis, et al. *J. Immunol.*, 156(8): 2700-9) and B7.2 (CD86; Ellis, et al. *J. Immunol.*, 156(8): 2700-9); polypeptides which bind members of
25

the integrin family (i.e., LFA-1 (CD11a / CD18); Sedwick, et al. *J Immunol* 1999, 162: 1367–1375; Wülfing, et al. *Science* 1998, 282: 2266–2269; Lub, et al. *Immunol Today* 1995, 16: 479–483) including members of the ICAM family (i.e., ICAM-1, -2 or -3); polypeptides which bind CD2 family members (i.e., CD2, signalling lymphocyte activation molecule (CDw150 or “SLAM”; Aversa, et al. *J Immunol* 1997, 158: 4036–4044) such as CD58 (LFA-3; CD2 ligand; Davis, et al. *Immunol Today* 1996, 17: 177–187) or SLAM ligands (Sayos, et al. *Nature* 1998, 395: 462–469); polypeptides which bind heat stable antigen (HSA or CD24; Zhou, et al. *Eur J Immunol* 1997, 27: 2524–2528); polypeptides which bind to members of the TNF receptor (TNFR) family (i.e., 4-1BB (CD137; Vinay, et al. *Semin Immunol* 1998, 10: 481–489)), OX40 (CD134; Weinberg, et al. *Semin Immunol* 1998, 10: 471–480; Higgins, et al. *J Immunol* 1999, 162: 486–493), and CD27 (Lens, et al. *Semin Immunol* 1998, 10: 491–499) such as 4-1BBL (4-1BB ligand; Vinay, et al. *Semin Immunol* 1998, 10: 481–48; DeBenedette, et al. *J Immunol* 1997, 158: 551–559), TNFR associated factor-1 (TRAF-1; 4-1BB ligand; Saoulli, et al. *J Exp Med* 1998, 187: 1849–1862, Arch, et al. *Mol Cell Biol* 1998, 18: 558–565), TRAF-2 (4-1BB and OX40 ligand; Saoulli, et al. *J Exp Med* 1998, 187: 1849–1862; Oshima, et al. *Int Immunol* 1998, 10: 517–526, Kawamata, et al. *J Biol Chem* 1998, 273: 5808–5814), TRAF-3 (4-1BB and OX40 ligand; Arch, et al. *Mol Cell Biol* 1998, 18: 558–565; Jang, et al. *Biochem Biophys Res Commun* 1998, 242: 613–620; Kawamata S, et al. *J Biol Chem* 1998, 273: 5808–5814), OX40L (OX40 ligand; Gramaglia, et al. *J Immunol* 1998, 161: 6510–6517), TRAF-5 (OX40 ligand; Arch, et al. *Mol Cell Biol* 1998, 18: 558–565; Kawamata, et al. *J Biol Chem* 1998, 273: 5808–5814), and CD70 (CD27 ligand; Couderc, et al. *Cancer Gene Ther.*, 5(3): 163–75). CD154 (CD40 ligand or “CD40L”; Gurunathan, et al. *J Immunol*, 1998, 161: 4563–4571; Sine, et al. *Hum. Gene Ther.*, 2001, 12: 1091–1102). Other co-stimulatory molecules may also be suitable for practicing the present invention.

One or more cytokines may also be suitable co-stimulatory components or “adjuvants”, either as polypeptides or being encoded by nucleic acids contained within the compositions of the present invention (Parmiani, et al. *Immunol Lett* 2000 Sep 15; 74(1): 41–4; Berzofsky, et al. *Nature Immunol* 1: 209–219). Suitable cytokines include, for example, interleukin-2 (IL-2) (Rosenberg, et al. *Nature Med.* 4: 321–327 (1998)), IL-

4, IL-7, IL-12 (reviewed by Pardoll, 1992; Harries, et al. *J. Gene Med.* 2000 Jul-Aug;2(4):243-9; Rao, et al. *J. Immunol.* 156: 3357-3365 (1996)), IL-15 (Xin, et al. *Vaccine*, 17:858-866, 1999), IL-16 (Cruikshank, et al. *J. Leuk Biol.* 67(6): 757-66, 2000), IL-18 (*J. Cancer Res. Clin. Oncol.* 2001. 127(12): 718-726), GM-CSF (CSF 5 (Disis, et al. *Blood*, 88: 202-210 (1996)), tumor necrosis factor-alpha (TNF- α), or interferon-gamma (INF- γ). Other cytokines may also be suitable for practicing the present invention.

Chemokines may also be utilized. For example, fusion proteins comprising CXCL10 (IP-10) and CCL7 (MCP-3) fused to a tumor self-antigen have been shown to 10 induce anti-tumor immunity (Biragyn, et al. *Nature Biotech.* 1999, 17: 253-258). The chemokines CCL3 (MIP-1 α) and CCL5 (RANTES) (Boyer, et al. *Vaccine*, 1999, 17 (Supp. 2): S53-S64) may also be of use in practicing the present invention. Other suitable chemokines are known in the art.

It is also known in the art that suppressive or negative regulatory immune 15 mechanisms may be blocked, resulting in enhanced immune responses. For instance, treatment with anti-CTLA-4 (Shrikant, et al. *Immunity*, 1996, 14: 145-155; Sutmuller, et al. *J. Exp. Med.*, 2001, 194: 823-832), anti-CD25 (Sutmuller, *supra*), anti-CD4 (Matsui, et al. *J. Immunol.*, 1999, 163: 184-193), the fusion protein IL13Ra2-Fc (Terabe, et al. *Nature Immunol.*, 2000, 1: 515-520), and combinations thereof (i.e., anti-CTLA-4 and 20 anti-CD25, Sutmuller, *supra*) have been shown to upregulate anti-tumor immune responses and would be suitable in practicing the present invention.

An immunogen may also be administered in combination with one or more adjuvants to boost the immune response. Adjuvants may also be included to stimulate or enhance the immune response against the immunogen. Non-limiting examples of 25 suitable adjuvants include those of the gel-type (i.e., aluminum hydroxide/phosphate ("alum adjuvants"), calcium phosphate), of microbial origin (muramyl dipeptide (MDP)), bacterial exotoxins (cholera toxin (CT), native cholera toxin subunit B (CTB), *E. coli* labile toxin (LT), pertussis toxin (PT), CpG oligonucleotides, BCG sequences, tetanus toxoid, monophosphoryl lipid A (MPL) of, for example, *E. coli*, *Salmonella mimesota*, 30 *Salmonella typhimurium*, or *Shigella flexneri*), particulate adjuvants (biodegradable, polymer microspheres), immunostimulatory complexes (ISCOMs)), oil-emulsion and

surfactant-based adjuvants (Freund's incomplete adjuvant (FIA), microfluidized emulsions (MF59, SAF), saponins (QS-21)), synthetic (muramyl peptide derivatives (murabutide, threony-MDP), nonionic block copolymers (L121), polyphosphazene (PCCP), synthetic polynucleotides (poly A:U, poly I:C), thalidomide derivatives (CC-5 4407/ACTIMID)), RH3-ligand, or polylactide glycolide (PLGA) microspheres, among others. Fragments, homologs, derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity. Suitable mutants or variants of adjuvants are described, e.g., in WO 95/17211 (Arg-7- Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant).
10 Additional LT mutants that can be used in the methods and compositions of the invention include, e. g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other suitable adjuvants are also well-known in the art.

As an example, metallic salt adjuvants such alum adjuvants are well-known in the art as providing a safe excipient with adjuvant activity. The mechanism of action of these 15 adjuvants are thought to include the formation of an antigen depot such that antigen may stay at the site of injection for up to 3 weeks after administration, and also the formation of antigen/metallic salt complexes which are more easily taken up by antigen presenting cells. In addition to aluminium, other metallic salts have been used to adsorb antigens, including salts of zinc, calcium, cerium, chromium, iron, and berilium. The hydroxide 20 and phosphate salts of aluminium are the most common. Formulations or compositions containing aluminium salts, antigen, and an additional immunostimulant are known in the art. An example of an immunostimulant is 3-de-O-acylated monophosphoryl lipid A (3D-MPL).

Any of these components may be used alone or in combination with other agents. 25 For instance, it has been shown that a combination of CD80, ICAM-1 and LFA-3 ("TRICOM") may potentiate anti-cancer immune responses (Hodge, et al. *Cancer Res.* 59: 5800-5807 (1999). Other effective combinations include, for example, IL-12 + GM-CSF (Ahlers, et al. *J. Immunol.*, 158: 3947-3958 (1997); Iwasaki, et al. *J. Immunol.* 158: 4591-4601 (1997)), IL-12 + GM-CSF + TNF- α (Ahlers, et al. *Int. Immunopharmacol.* 13: 897-30 908 (2001)), CD80 + IL-12 (Fruend, et al. *Int. J. Cancer*, 85: 508-517 (2000); Rao, et al. *supra*), and CD86 + GM-CSF + IL-12 (Iwasaki, *supra*). One of skill in the art would be

aware of additional combinations useful in carrying out the present invention. In addition, the skilled artisan would be aware of additional reagents or methods that may be used to modulate such mechanisms. These reagents and methods, as well as others known by those of skill in the art, may be utilized in practicing the present invention.

5 Other agents that may be utilized in conjunction with the compositions and methods provided herein include anti-HIV agents including, for example, protease inhibitor, an HIV entry inhibitor, a reverse transcriptase inhibitor, and / or an anti-retroviral nucleoside analog. Suitable compounds include, for example, Agenerase (amprenavir), Combivir (Retrovir / Epivir), Crixivan (indinavir), Emtriva (emtricitabine),
10 Epivir (3tc / lamivudine), Epzicom, Fortovase / Invirase (saquinavir), Fuzeon (enfuvirtide), Hivid (ddc / zalcitabine), Kaletra (lopinavir), Lexiva (Fosamprenavir), Norvir (ritonavir), Rescriptor (delavirdine), Retrovir / AZT (zidovudine), Reyataz (atazanavir, BMS-232632), Sustiva (efavirenz), Trizivir (abacavir / zidovudine / lamivudine), Truvada (Emtricitabine / Tenofovir DF), Videx (ddl / didanosine), Videx
15 EC (ddl, didanosine), Viracept (nevirapine), Viread (tenofovir disoproxil fumarate), Zerit (d4T / stavudine), and Ziagen (abacavir). Other suitable agents are known to those of skill in the art. Such agents may either be used prior to, during, or after administration of the compositions and / or use of the methods described herein.

20 Administration of a composition of the present invention to a host may be accomplished using any of a variety of techniques known to those of skill in the art. The composition(s) may be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals (i.e., a "pharmaceutical composition"). The pharmaceutical composition is
25 preferably made in the form of a dosage unit containing a given amount of DNA, viral vector particles, polypeptide, peptide, or other drug candidate, for example. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods. The compositions are administered to a patient in a form and amount sufficient to elicit a therapeutic effect. Amounts effective for this use will depend on various factors, 30 including for example, the particular composition of the vaccine regimen administered, the manner of administration, the stage and severity of the disease, the general state of

health of the patient, and the judgment of the prescribing physician. The dosage regimen for immunizing a host or otherwise treating a disorder or a disease with a composition of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of 5 administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.

In general, recombinant viruses may be administered in compositions in a dosage amount of about 10^4 to about 10^9 pfu per inoculation; often about 10^4 pfu to about 10^6 pfu, or as shown in the Examples, 10^7 to 10^8 pfu. Higher dosages such as about 10^3 pfu to 10 about 10^{10} pfu, e.g., about 10^5 pfu to about 10^9 pfu, or about 10^6 pfu to about 10^8 pfu, or about 10^7 pfu can also be employed. Another measure commonly used is cell culture 15 infective dose (CCID₅₀); suitable CCID₅₀ ranges for administration include about 10^1 , about 10^2 , about 10^3 , about 10^4 , about 10^5 , about 10^6 , about 10^7 , about 10^8 , about 10^9 , about 10^{10} CCID₅₀. Ordinarily, suitable dosage amounts of plasmid or naked DNA are 20 about 1 μ g to about 100 mg, about 1 mg, about 2 mg, but lower levels such as 0.1 to 1 mg or 1-10 μ g may be employed. For polypeptide compositions (e.g., AIDSVAX compositions), a suitable amount may be 1-1000 μ g. Without limiting the possible sub-ranges within that dosage range, particular embodiments may employ 5, 10, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, and 25 1000 μ g. A typical exemplary dosage of polypeptide may be, for example, about 50-250 μ g, about 250-500 μ g, 500-750 μ g, or about 1000 μ g of polypeptide. Low dose administration may typically utilize a dose of about 100 μ g or less. High dose administration may typically utilize a dose of 300 μ g or more. In referring to the amount 30 of polypeptide in a dose, it is to be understood that the amount may refer to the amount of a single polypeptide or, where multiple polypeptides are administered, to the total amount of all polypeptides (e.g., 300 μ g each of two polypeptides for a total administration of 600 μ g). The AIDSVAXTM compositions described herein are typically but not necessarily administered in a total dosage of 200 μ g or 600 μ g (e.g., recombinant MN and GNE8 gp120, or recombinant MN and A244 gp120). "Dosage" may refer to that administered in a single or multiple doses, including the total of all doses administered.

Actual dosages of such compositions can be readily determined by one of ordinary skill in the field of vaccine technology.

The pharmaceutical composition may be administered orally, parentally, by inhalation spray, rectally, intranodally, or topically in dosage unit formulations 5 containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a nucleic acid, polypeptide, or peptide as a pharmaceutical composition. A "pharmaceutical composition" is a composition comprising a 10 therapeutically effective amount of a nucleic acid or polypeptide. The terms "effective amount" and "therapeutically effective amount" each refer to the amount of a nucleic acid or polypeptide used to observe the desired therapeutic effect (e.g., induce or enhance and immune response).

Injectable preparations, such as sterile injectable aqueous or oleaginous 15 suspensions, may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution, among others. For instance, a viral vector such as a 20 poxvirus may be prepared in 0.4% NaCl or a Tris-HCl buffer, with or without a suitable stabilizer such as lactoglutamate, and with or without freeze drying medium. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or 25 diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Pharmaceutical compositions may take any of several forms and may be administered by any of several routes. The compositions are administered via a parenteral route (e.g., intradermal, intramuscular, subcutaneous, skin scarification) to induce an immune response in the host. Alternatively, the composition may be 30 administered directly into a tissue or organ such as a lymph node (e.g., intranodal) or tumor mass (e.g., intratumoral). Preferred embodiments of administratable compositions

include, for example, nucleic acids, viral particles, or polypeptides in liquid preparations such as suspensions, syrups, or elixirs. Preferred injectable preparations include, for example, nucleic acids or polypeptides suitable for parental, subcutaneous, intradermal, intramuscular or intravenous administration such as sterile suspensions or emulsions. For 5 example, a naked DNA molecule and / or recombinant poxvirus may separately or together be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like. The composition may also be provided in lyophilized form for reconstituting, for instance, in isotonic aqueous, saline buffer. In addition, the compositions can be co-administered or sequentially administered with one 10 another, other antiviral compounds, other anti-cancer compounds and/or compounds that reduce or alleviate ill effects of such agents.

As previously mentioned, while the compositions described herein may be administered as the sole active agent, they can also be used in combination with one or more other compositions or agents (i.e., other immunogens, co-stimulatory molecules, 15 adjuvants). When administered as a combination, the individual components can be formulated as separate compositions administered at the same time or different times, or the components can be combined as a single composition. In one embodiment, a method of administering to a host a first form of an immunogen and subsequently administering a second form of the immunogen, wherein the first and second forms are different, and 20 wherein administration of the first form prior to administration of the second form enhances the immune response resulting from administration of the second form relative to administration of the second form alone, is provided. Also provided are compositions for administration to the host. For example, a two-part immunological composition where the first part of the composition comprises a first form of an immunogen and the 25 second part comprises a second form of the immunogen, wherein the first and second parts are administered together or separately from one another such that administration of the first form enhances the immune response against the second form relative to administration of the second form alone, is provided. The immunogens, which may be the same or different, are preferably derived from the infectious agent or other source of 30 immunogens. The multiple immunogens may be administered together or separately, as a single or multiple compositions, or in single or multiple recombinant vectors. For

instance, a viral vector encoding an immunogen may be initially administered and followed by one or more subsequent administrations with a second form of the immunogen (e.g., a polypeptide). The different forms may differ in either or both of the form of delivery (e.g., viral vector, polypeptide) or in the immunogens represented by 5 each form. It is preferred that the forms, however, induce or enhance the immune response against a particular target (e.g., HIV-1). For instance, as shown herein, a viral vector encoding a viral antigen (e.g., HIV gp120) may be administered to a human being. This may then be followed by administration of the viral vector along with a polypeptide representing the same or a similar viral antigen (e.g., HIV gp120). For prime-boost 10 applications (e.g., ALVAC-HIV and AIDSVAXTM), ALVAC-HIV is typically administered in a 10^7 CCID₅₀ dosage (the “priming” dose), and then subsequently re-administered at the same or different dosage along with a suitable dosage (e.g., 600 μ g total, the “boosting” dose) of polypeptide (e.g., AIDSVAXTM B/B or B/E). ALVAC-HIV 15 is a preparation of live attenuated, recombinant canarypox virus (ALVAC(I)) expressing gene products from the HIV-1 *env* (clade E in vCP1521 and clade B in vCP205), *gag* (clade B), and *protease* (clade B) coding sequences (Fig. 2). Exemplary, non-limiting prime-boost combinations may include ALVAC-HIV (vCP205) and AIDSVAXTM B/B or ALVAC-HIV (vCP1521) and AIDSVAXTM B/E, as the HIV clades from which the gp120 immunogen is derived in those combinations are the same. Typically, both the 20 priming and boosting doses are administered via the same route (e.g., intramuscular, intradermal) but the routes of administration may also be different. Typically, the priming and boosting doses are administered to different parts of the body, but the doses may also be administered to the same part of the body. “Along with” may mean that the two forms are administered as separate compositions, as part of a single composition, at 25 separate sites of the body, or at the same site of the body, depending on the particular protocol. Variations of such exemplary dosing regimens may be made by those of skill in the art.

A kit comprising a composition of the present invention is also provided. The kit can include a separate container containing a suitable carrier, diluent or excipient. The kit 30 may also include additional components for simultaneous or sequential-administration. In one embodiment, such a kit may include a first form of an immunogen and a second

form of the immunogen. Additionally, the kit can include instructions for mixing or combining ingredients and/or administration. A kit may provide reagents for performing screening assays, such as one or more PCR primers, hybridization probes, and / or biochips, for example.

5 A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.

EXAMPLES

Example 1

10 *Immunological Compositions*

A. **First composition: viral vector**

ALVAC-HIV is a preparation of live attenuated, recombinant canarypox virus (ALVAC(1)) expressing gene products from the HIV-1 *env* (clade E in vCP1521 and clade B in vCP205), transmembrane anchoring portion of gp41 (clade B:LAI), *gag* (clade 15 B:LAI), and protease (clade B:LAI) coding sequences and cultured in chick embryo fibroblast cells. These vectors were generated by co-insertion of genes encoding HIV-1 gene products into the ALVAC(1) genome at the C6 insertion site using standard techniques (Fig. 2A). The HIV-1 sequences contained within ALVAC-HIV (vCP1521) are shown in Fig. 2B and SEQ ID NOS.:5 and 6. These sequences include: 1) the region 20 of the *env* gene encoding the extracellular envelope gp120 moiety of TH023 strain of HIV-1 linked to the sequences encoding the HIV-1 transmembrane anchor sequence of gp41 (28 amino acids), under the control of the vaccinia virus H6 promoter; and, 2) the *gag* gene encoding the entire Gag protein, and a portion of the *pol* sequences of LAI strain of HIV-1 sufficient to encode the protease function, under the control of the same 25 vaccinia virus promoter I3L.

ALVAC-HIV was produced by inoculation of the ALVAC-HIV working seed lot in primary chick embryo fibroblasts and cultivation in roller bottles. After viral amplification, the infected cells were harvested and disrupted by sonication and cell debris removed by centrifugation. An equal volume of stabilizer (lactoglutamate) was 30 blended with the supernatant and the suspension filtered through a 4.5 μ m membrane. The clarified suspension was filled into vials and stored at $\leq 35^{\circ}\text{C}$. At this step, the

biological substance is the clarified harvest. End stage manufacturing of the vaccine entails blending of the clarified harvest with the freeze drying medium under sterile conditions. This blend (final bulk product) was prepared and then filled and freeze dried.

5 Immunoprecipitation analyses were performed using radiolabelled lysates derived from uninfected CEF cells or cells infected with either ALVAC(1) parental virus or ALVAC-HIV. Immunoprecipitation was performed using human serum derived from HIV-seropositive individuals (anti-HIV). Results with anti-HIV demonstrated expression of gp120, the 55 kDa precursor Gag polypeptide, and intermediate and completely processed forms of Gag including the major capsid protein, p24 in ALVAC-HIV infected 10 CEF cells but not from cells infected with ALVAC parental virus.

Regarding ALVAC-HIV (vCP1521), FACS (Fluorescent Activated Cell Sorter) scan analyses with human anti-HIV antibody demonstrated expression of gp120 on the surface of infected HeLa, but not the parental virus. PCR amplification of the inserted sequences and those of ALVAC was performed. DNA analysis was performed by 15 agarose gel electrophoresis followed by ethidium bromide staining to confirm the identity of the amplified fragments according to their molecular size. Restriction analysis was performed on viral DNA derived from ALVAC-HIV (vCP1521) infected cells to confirm proper insertion of the gp120TM and gag expressing cassettes. The nucleotide sequence of inserted genes was confirmed by sequencing on the Working Seed Lot (passage 6).

20 ALVAC-HIV (vCP1521) genetic stability was confirmed by immunoplaque assay after several passages on CEF. Immunoplaque analysis consisted of detecting Env and Gag expression in viral plaques by monoclonal antibodies. Analysis was performed after 7 passages (i.e. at the production lot level) and after 10 passages (i.e. 3 passages beyond the production lot level).

25 ALVAC-HIV (vCP1521) was formulated as a lyophilized vaccine for injection and reconstituted with 1.0 mL of sterile sodium chloride solution (NaCl 0.4%) for a single dose. The composition of the vaccine after reconstitution with 1.0 mL NaCl 0.4% included ALVAC-HIV (vCP1521); $\geq 10^{6.0}$ CCID₅₀ and excipients (TRIS-HCl buffer 10 mM, pH 9, 0.25 mL; stabilizer (lactoglutamate), 0.25 mL; freeze-drying medium, 0.50 30 mL; and NaCl, 4 mg). The appearance of the lyophilisate was homogeneous, white to beige; residual moisture was $\leq 3\%$; reconstitution time was ≤ 3 minutes; the appearance

after reconstitution was a limpid to slightly opalescent solution, colorless with possible presence of particles or filaments; pH between 7.0 and 8.0; osmolality between 350 to 700 mOsmol/kg; BSA content of ≤50 ng/dose; bacterial endotoxins content of ≤10 IU/dose. The ALVAC-HIV (vCP1521) was stored at 2-8 °C without freezing and 5 administered within 2 hours of reconstitution. Prior to reconstitution, the vial was allowed to come to room temperature. Each vial was reconstituted with the diluent supplied, 1.0 mL 0.4% NaCl for administration by slow injection into the vial containing the lyophilized ALVAC-HIV (e.g., using a 25 gauge, 5/8- inch needle). The vial was allowed to sit for approximately three minutes, and then gently swirled. The vial was 10 then inverted and the contents withdrawn into a syringe.

B. Second composition: polypeptide

Recombinant gp120 is an envelope glycoprotein with an apparent molecular mass of about 120,000 daltons. Approximately 50% of the molecular mass is accounted for by 15 extensive glycosylation of the protein. AIDSVATM vaccines are highly purified mixtures of gp120 proteins from HIV-1 produced by recombinant DNA procedures using Chinese hamsters ovary (CHO) cell expression. Molecular epidemiologic analyses of virus circulating in the US has documented polymorphisms occur at the major neutralizing epitopes of gp120. Analysis of breakthrough infections in Phase I and Phase 20 II trials of MN rgp120/HIV-1 revealed that most contained amino acid substitutions that differed from MN rgp120/HIV-1 at epitopes important for virus neutralization (specifically at the V2, V3 and C4 domains). After examining a variety of US strains, GNE8 was selected because amino acid sequences at sites known to be target of neutralizing antibodies differed from MN and possessed common polymorphisms that 25 complemented MN at major neutralizing epitopes. Thus, an exemplary polypeptide composition is AIDSVATM B/B (VaxGen), which contains a bivalent polypeptide vaccine containing the HIV-1 type B epitopes MN recombinant glycoprotein (rgp)120 (amino acids 12-485 of MN gp120) and GNE8 rgp120 (amino acids 12-477 of GNE8 gp120) at a one-to-one ratio. Another exemplary polypeptide composition for use where 30 subtypes B and E are prevalent (e.g., Thailand) is AIDSVATM B/E, which contains the subtype B antigen MN rgp120 (as described above) and the subtype E antigen A244

(CM244) recombinant glycoprotein 120 (amino acids 12-484 of A244 gp120) at a one-to-one ratio. The subtype E antigen is derived from the A244 (CM244) strain of HIV-1, which is isolated from Chiang Mai in Northern Thailand and represents about 75% of the incident infections in intravenous drug users (IVDUs) in Bangkok. A244 rgp120/HIV-1 is derived from a primary, macrophage or NSI viral type and, like GNE8 rgp120/HIV-1, requires the chemokine receptor CCR5 to bind with CD4 cells.

5 In both AIDSVAX™ B/B and AIDSVAX™ B/E, gp120 of the MN, GNE8, or A244 strains are each expressed as an amino-terminal fusion protein with a 27 amino acids of the herpes simplex virus type I gD protein. The gD sequence facilitates gp120 expression and provides an epitope that can be used in a generic immunoaffinity 10 purification process. The amino acid residues equivalent to the mature, native gp120 for each particular HIV-1 isolate utilized are: 12 to 485 for the MN isolate, 12 to 477 for the GNE8 isolate, and 12 to 484 for the A244 isolate.

15 The recombinant gp120 polypeptides are produced in genetically modified CHO cell line. The CHO cells secrete the rgp120/HIV-1 molecule into the culture medium, and the protein is purified by a generic purification process for gp120 that includes immunoaffinity chromatography. AIDSVAX™ bivalent vaccines are supplied as a sterile suspension in single-use glass vials. Each vial has a nominal content of 1 mL 20 (300 µ/mL) of each rgp120/HIV-1 protein adsorbed onto a total of 0.6 mg aluminum hydroxide gel adjuvant.

Example 2

Clinical Trial Design and Results

25 A prime-boost immunization protocol, using as the "prime" composition ALVAC-HIV (vCP1521) and the "boost" composition AIDSVAX® B/E was tested in a formal phase III clinical trial. The trial described herein was a community-based, randomized (vaccine: placebo = 1:1), multicenter, double blind, placebo-controlled clinical trial conducted in Thailand. The primary objective of the study was to determine if vaccination with ALVAC-HIV (vCP1521) and AIDSVAX® B/E could prevent HIV 30 infection in healthy Thai adults. Thus, infection rates, as well as plasma viral load and CD4+ T cell counts in volunteers developing HIV infection during the trial, were

assessed. The statistical assumptions of the study required that 16,000 persons enroll into the study. Intramuscular vaccinations (e.g., deltoid muscle) for each individual occurred during a 24-week period (0, 4, 12, 24 weeks). Following vaccination, the volunteers were tested for the presence of HIV in their plasma every 6 months for 3 years.

5 The “first composition” (ALVAC-HIV), as described in Example 1A above was initially administered to patients as the priming dose at months 0, 1, 3 and 6 (weeks 0, 4, 12 and 24). The “second composition” (AIDSVAX® B/E) was later administered at months 3 and 6 (weeks 12 and 24 as for ALVAC-HIV) as the boosting dose. ALVAC-HIV doses included approximately 10^7 CCID₅₀. AIDSVAX® B/E doses included 10 approximately 600 µg of polypeptide (300 µg of each of B and E). There was a 3 year follow-up with vaccine volunteers (Rerks-Ngram, 2009, NEJM 361:2209). The trial design is summarized in **Table 2**, as shown below:

Table 2
RV144 Trial Design

Group	Number	Weeks			
		0	4	12	24
I	8,000	ALVAC Placebo	ALVAC Placebo	ALVAC Placebo + AIDSVAX Placebo	ALVAC Placebo + AIDSVAX Placebo
II	8,000	ALVAC-HIV	ALVAC-HIV	ALVAC-HIV + AIDSVAX® B/E	ALVAC-HIV + AIDSVAX® B/E

15

As shown in **Fig. 3**, the two-part composition was used in a prime-boost format to successfully vaccinate human beings with an efficacy of 31.2% (e.g., about one-third of the population). The population to whom a placebo was administered exhibited 74 HIV infections over the testing period, while those administered the ALVAC-HIV / 20 AIDSVAX® B/E two-part composition (“vaccine”) exhibited 51 HIV infections over the testing period. The difference in the number of HIV infections between the two groups was statistically significant ($p=0.039$). In patients that were infected by HIV after vaccination, neither the setpoint viral load nor mean CD4+ T cell counts were significantly different from placebo at 30 months post-vaccination. This is the first 25 vaccine shown to reduce the risk of HIV infection in human beings compared to a

placebo. The observed vaccine efficacy was 31.2% ($p = 0.0385$, O'Brien-Fleming adjusted 95% CI 1.1, 52.1) using the Cox Proportional Hazard method. Thus, this is the first demonstration of a safe, efficacious vaccine that is capable of protecting human beings from infection by HIV.

5

It is to be understood that any reference to a particular range includes all individual values and sub-ranges within that range as if each were individually listed herein. All references cited within this application are incorporated by reference in their entirety. While the present invention has been described in terms of the preferred embodiments, it is understood that variations and 10 modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the invention as claimed.

References

- 15 Burton, et al. *Science*, 303:316 (2004)
de Bruyn, et al. *Vaccine*, 22:704-13 (2004)
Esposito, et al. (eds); *Arch. Virol. Supp. 2*. NY, Springer-Verlag, pp 91-102 (1991)
Fang, et al. *J. Infect. Dis.* 180 (4): 1122-32 (1999)
Ferrari, et al. *Proc. Natl. Acad. Sci. USA* 94:1396-401 (1997)
- 20 Klausner, et al. *Science*, 300:2036-39 (2003)
Letters to the Editor. *Science*, 305:177-180 (2004)
McCarthy M. *Lancet*. Nov 22;362(9397):1728 (2003)
McNeil, et al. *Science*, 303:961 (2004)
Meeting Summary: AIDS Vaccine Trials, Considerations for Phase III Trial Design and
- 25 Endpoints. National Institutes of Health, NIAID, November 16, 2001. Retrieved from the World Wide Web on August 3, 2004 at <http://www.niaid.nih.gov/vrc>.
NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed.
NIAID News, February 25, 2002. Retrieved from the World Wide Web on August 9, 2004 at <http://www2.niaid.nih.gov/newsroom/releases/phase3hiv.htm>.
- 30 Nitayaphan, et al. *J. Inf. Dis.* 190:702-6 (2004)
Rerks-Ngarm et al *NEJM*, 361:2209 (2009)

Tangcharoensathien, et al. *Health Policy*, 57:111-139 (2001)

Tartaglia, et al. (eds): *AIDS Research Reviews*, Vol.3. New York, Marcel Dekker, pp 361-378 (1993).

Tovanabutra S, et al. *AIDS Vaccine* 2003, New York, NY; Abstract number 463.

5 Trinvuthipong, D. *Science*, 303:954-5 (2004)

CLAIMS

1. A method for protectively immunizing a human being against human immunodeficiency virus (HIV) by administering to the human being:

5 a first composition comprising multiple doses of an avipox vector encoding at least a portion of HIV gp120 and, subsequently,

10 a second composition comprising multiple doses of a polypeptide corresponding to at least a portion of HIV gp120,

15 to a population of human beings that induces a protective immune response against infection by HIV in at least about one-third of the population, wherein:

10 a) one or more doses of the first composition is administered repeatedly to the population as the sole active agent; and,

15 b) one or more doses of the second composition is subsequently administered to the population as the sole active agent or in combination with one or more doses of the first composition.

20 2. The method of claim 1 wherein each dose of the avipox vector is equivalent to about 10 to about 10^{10} CCID₅₀.

25 3. The method of claim 2 wherein each dose of the avipox vector is equivalent to about 10^7 CCID₅₀.

4. The method of claim 1 wherein each dose of the polypeptide is about 5 to about 1000 μ g.

20 5. The method of claim 1 wherein each dose of the polypeptide is about 600 μ g.

6. The method of claim 1 wherein each dose of the avipox vector is equivalent to about 10^7 CCID₅₀ and each dose of the polypeptide is about 600 μ g.

7. The method of any one of claims 1-6 wherein the avipox vector comprises the nucleic acid sequence of SEQ ID NO:5.

25 8. The method of any one of claims 1-6 wherein the polypeptide of the second composition has the amino acid sequence of SEQ ID NO. 2 or 3.

9. The method of any one of claims 1-6 wherein the avipox vector comprises the nucleic acid sequence of SEQ ID NO:5 and the polypeptide of the second composition has the amino acid sequence of SEQ ID NO. 2 or 3.

10. The method of any one of claims 1-9 wherein the time between administrations of the first composition is four weeks.

11. The method of any one of claims 1-10 wherein the time between administrations of the first composition is eight weeks.

12. The method of any one of claims 1-11 wherein the second composition is repeatedly administered.

13. The method of any one of claims 1-12 wherein the second composition is repeatedly administered at a 12-week interval.

14. The method of any one of claims 1-13 wherein the first and second composition are repeatedly administered together in part b).

15. The method of any one of claims 1-14 wherein administration of both the first and second compositions is via a route selected from the group consisting of mucosal, intradermal, intramuscular, subcutaneous, via skin scarification, and intranodal.

16. The method of any one of claims 1-15 wherein the HIV is selected from the group consisting of HIV-2 subtype A, HIV-2 subtype B, HIV-2 subtype C, HIV-2 subtype D, and HIV-2 subtype E.

17. The method of any one of claims 1-16 further comprising administering a composition comprising at least one additional HIV immunogen selected from the group consisting of gag, pol, nef, a variant thereof, and a derivative thereof.

18. The method of any one of claims 1-17 wherein the avipox vector is ALVAC.

19. A kit when used to induce a protective immune response against infection by HIV in at least about one-third of the population, said kit comprising a first composition comprising multiple doses of an avipox vector encoding HIV gp120 and a second composition comprising multiple doses of a polypeptide corresponding to at least a portion of HIV gp120, and instructions for repeatedly administering one or more doses of the first composition to a human being and subsequently administering one or more doses of the second composition or the first and second compositions to the human being.

20. The kit of claim 19 wherein the instructions direct administration of two doses of the first composition alone followed by two doses of the first and second compositions in combination.

21. The kit of claim 19 or 20 wherein the instructions direct that each dose of the avipox vector is equivalent to about 10 to about 10^{10} CCID₅₀.

22. The kit of claim 21 wherein the instructions direct that each dose of the avipox vector is equivalent to about 10^7 CCID₅₀.

23. The kit of claim 19 wherein the instructions direct that each dose of the polypeptide is about 5 to about 1000 μ g.

24. The kit of claim 23 wherein the instructions direct that each dose of the polypeptide is about 600 μ g.

25. The kit of any one of claims 19-24 wherein the instructions direct that each dose of the avipox vector is equivalent to about 10^7 CCID₅₀ and each dose of the polypeptide is about 600 μ g.

26. The kit of any one of claims 19-25 the instructions direct that the time between administrations of the first composition is four weeks.

27. The kit of any one of claims 19-25 the instructions direct that the time between administrations of the first composition is eight weeks.

28. The kit of any one of claims 19-25 the instructions direct that the second composition is repeatedly administered.

29. The kit of claim 28 wherein the instructions direct that the second composition is repeatedly administered at a 12-week interval.

5 30. The kit of any one of claims 19-29 wherein the instructions direct that the first and second composition are repeatedly administered together following administration of the first composition alone.

10 31. The kit of any one of claims 19-30 wherein the instructions direct that administration of both the first and second compositions is via a route selected from the group consisting of mucosal, intradermal, intramuscular, subcutaneous, via skin scarification, and intranodal.

32. The kit of any one of claims 19-31 wherein the HIV is selected from the group consisting of HIV-2 subtype A, HIV-2 subtype B, HIV-2 subtype C, HIV-2 subtype D, and HIV-2 subtype E.

15 33. The kit of any one of claims 19-32 further comprising administering a composition comprising at least one additional HIV immunogen selected from the group consisting of gag, pol, nef, a variant thereof, and a derivative thereof.

34. The kit of any one of claims 19-33 wherein the avipox vector is ALVAC.

35. The kit of any one of claims 19-34 wherein the avipox vector comprises the nucleic acid sequence of SEQ ID NO:5.

20 36. The kit of any one of claims 19-34 wherein the polypeptide of the second composition has the amino acid sequence of SEQ ID NO. 2 or 3.

37. The kit of any one of claims 19-34 wherein the avipox vector comprises the nucleic acid sequence of SEQ ID NO:5 and the polypeptide of the second composition has the amino acid sequence of SEQ ID NO. 2 or 3.

Sanofi Pasteur, Inc.

The United States of America as represented by the Secretary of the Army, on behalf of

Walter Reed Army Institute of Research

Global Solutions for Infectious Diseases


Ministry of Public Health

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON

FIGURE 1

		gD leader sequence	gp120 sequence
gD244	1	KYALADASLKMADPNRERGKDELPVLDQOLLEYPVWKEAD	DTT1FCASDAKAY
MM.mature	1	KYALADASLKMADPNRERGKDELPVLDQOLLEYPVWKEATT	TTT1FCASDAKAY
gD244	51	E E V H N V W A T H A C V P T D P N P Q E I D L E N V T E N F N M W K N N M V E Q M D E Q D Y I S L	
MM.mature	51	D T E I A H N V W A T H A C V P T D P N P Q E V E L V N V T E N F N M W K N N M V E Q M H E D I I S L	
gD244	101	W Q S L K P C V K L T P C V T L R C T N A N L T K A N L T H V N N R T N V S H I S G N I I T D E	
MM.mature	101	W Q S L K P C V K L T P C V T L R C T D L R N T T N H S T D N H S K S E G T I K G S E	
gD244	150	Y R N C S F N M T T E L R D K K Q I V H A L P Y K L D I V P I E D N N D S E S Y R L I N C T S V I	
MM.mature	150	M K N C S F N M T T S I G D K M Q K E Y A L L Y K L D I E P I D - - N D S T S Y R L I N C T S V I	
gD244	200	K D A C P K I S F D P I P I H Y C T P A G Y A I L K C N S K N F N G T G P C K N Y S I V Q C T H G I	
MM.mature	197	T D A C P K I S F E P I P I H Y C A P A G F A I L K C N S K K F S G K G S C K N Y S T V Q C T H G I	
gD244	250	R P V V S T Q L L N G S L A E E E V I R S E N L T N W A K T I I V H L N K S V I N C T R P S N	
MM.mature	247	R P V V S T Q L L N G S L A E E E V Y I R S E D F T N W A K T I I V H L K E S V Q I N C T R P N Y	
gD244	300	N I P T S I I I G P G O V F Y R T G D I I G G I R K A Y D E I N G T E R N K A L K O V T E K L K E H	
MM.mature	297	N K R K R A I H I S P G R A F Y T T K N I K G T I R O A H D I I S R A K W N T I R O I V S K L K E G	
gD244	350	F F N K P I I I F O P P S G G D E I T N H H F N C G D E F F Y C H T T R E F N H T C I A N G I - -	
MM.mature	347	F K N K T I I V F N P S S G G D P E I V N H S F N C G D E F F Y C N T S P L F N S I W H G N N T W H N	
gD244	397	I E G C I N G N I T L P C K I K Q I I N N W Q G A G Q A M Y A P P I S G T I N C V S H I T B I L L T R	
MM.mature	397	T T G S I N N I T L G C K I K Q I I N N W Q K V G K A M Y A P P I E G Q I P C S I N T G B I L L T R	
gD244	437	D G G A T N N T H N - E I T F R P G G G N I K D N W P N E L Y K Y K V V I I E P L G V A F T R A K K R	
MM.mature	437	D G G E D T D Y N O T E I F R P G G G D M R O N W R S E L Y K Y K V V I I E P L G V A F T K A K K R	
gD244	485	V V E R E K R SEQ ID NO.: 2	
MM.mature	487	V V I O R E K R SEQ ID NO.: 3	

FIGURE 2**A. ALVAC-HIV Genome****B. Nucleotide sequence of the vCP1521 Insert**

10

C6 flanking arm

15

1 AGTACGATATA AAAGTATTAA ATTAATAATAC TTACGTTGCGA AAAGATGCTGTT ATTAGCTAT
TTCTGTTATT TTYTCATAATTT TATTTTTTAACT ATATGATGTT TTTTTTACGTT TTATGTTATA

20

121 TCTTAAACGCT ATGAAAGCTC CTACTTCTAT TATGATATACT TTTTTTTCCTC TTCTCAGCTG
ATAATTTGAG TGTGTTGAG GATGATATACT ATACATATACT GAAAAAGAAT AGAGCTGGG

25

181 HIV-1 Env (Clade E)
TCTTCCTTCTG GGGGGGGGGG GGGCTCTTCG TAGGGCTGCA ATTCGGTACTA CTCTTATTT
AGAGAGAAGC CGGGGGGGGG CACGTTGAGG ATTCGATGTT TAACTGATGAT GATTTATGAA

30

241 HIV-1 Env (Clade E)
ATATGATCTCA CTTCCTGCTTC TGTGCTTCTG ATTCGGTCTG AGCTCTGGTT
TATATGAGT GAGAGGGTTA ACAGGAGATA TAAAGGAGCA GGTGAGAGCT TGTGAGGAA

35

301 HIV-1 Env (Clade E)
AGTATTGATTG AGACGACGAT CTGCTGCTCA TATGTTCTCT TGAATTTTTT ATTCGAGTT
TCTTAAATAC TTGTTGTTGAG GAGAGGCTGTT ATTCGAGTT GATTTATAC TATGTTGTTA

40

361 HIV-1 Env (Clade E)
AATTCGTTT ATCTTCTGAT GAGGAGATG ATCTGCTTCG CACCCCTGCA TGTGTTCTT
TTAAAGGAAA TAAAGGAGTA CTTCATACCA TCACTGTTAT GGGGGGGGGT ATTCGAGTT

45

421 HIV-1 Env (Clade E)
TTCCATGCA GATTTATTAAC AGCTGCTGTT TGTGTTGCA TAGAGGTTT CCGCTCTACA
AAGGTTAGTTT CATAATTTAT TGTGAGGAA AGCTACCTT ATTCGTTCA GGGGGGGGGT

50

481 HIV-1 Env (Clade E)
ATTTAAATGA TCTCTTCTAA TTTCCTTCTG TCTCTTCTGAG AGTTTATTTT
TCTTTTGTGTTT GAGGAGTTT AGAGAGGAG AGGGGGGGGG GGGGGGGGGT TGTGTTGACA

55

541 HIV-1 Env (Clade E)
CTTTTTTTTA AGTGTGTTT TTATTTTTTT AGCTCTCTT TTAAAGCTT CTCTGTTTT
GAAATATATA TTGCGGAGCA ATATGAAATA TCAATGAGAA TAACTGAGAA TAACTGAGAA

601 HIV-1 Env (Clade E)
TGTGCGCTTA ATCTGAGAT AGCTGTTCTT TAACTGCTCT TGTGTTCTGTT
AGAGAGTTAT TAACTGTTTA TAACTGAGAA ATATGAGAA TAACTGAGAA TAACTGAGAA

HIV-1 Env (Clade E)

721 GAACTCTCTG CTCGTCGCTA TATTAATCTG TCTTCTTCG TCTGGGAGG TCTGGGTCG
CTTATGAGCA GAAAGGAGAT ATATAATATA AGACAGAGAT AGAACATTCG CAAACGCTGT

5 HIV-1 Env (Clade E)

761 ATGGATTCTG AGACAGTTAT TACGGTGCG TATTATGGCT TCTGGATGT TCTGCTGTT
TAATCAAGA TCTCTCTAATA ATTCAGCTG ATATAACCA AACGCTTACA AACGCTTAA

10 HIV-1 Env (Clade E)

841 TCTGAGATG ATTAATTTAT CTTGTCGCG TATTAATCG ATTCGCTGA
AGCTCTAGC TTAATATGCA GAAAGGAGCG ATCTGGCTG ATATTCGCT TCTGGCTGT

15 HIV-1 Env (Clade E)

901 TACGGACGG TTAATTCGAT CTGTCGCTG TCTGGCTG AGATTTTCG ATGGCTGT
ATGGCTGGC ATTAAGGCTA CTCACGAGAC ATGGCTGAG CTTAAAGTC TCCGGGACA

20 HIV-1 Env (Clade E)

961 CCCTTGAAA TCTTCTATCT TACACTTCTA ATACGCTAA CCTGGCGAG TACATTAATG
GGTTAATCTT AGAAATATGA ATGGCTGAACT TTAATGCTT CCTGGCTG ATGTTTATTC

25 HIV-1 Env (Clade E)

1021 TATAGGAAAT GGTGTCAGG ATATCTTCTG AGACGCGCG TTATGCTG AGCTTATCA
ATACGCTTA CCTAGCTTCC TATTAAGAC TCTGGCGG ATATCTGAC TTCTATGAT

30 HIV-1 Env (Clade E)

1081 ATTTATTAAC CTATACCTAC TACTACGCT CTTGGTCTCA ATTCGCTTA TATTAATCTG
TCAATGATG GATATGAGG ATGATGAGCA CAAAGGAGT TAACTGAT ATTTCTTCA

35 HIV-1 Env (Clade E)

1141 GTGAAATAGT GGTGTCAGCT TCTGGCTGTT ATCTGTTATG TCTGGGCGA TATTAAGA
CTATCTCTCA CCTACGCTGA AGACAGAGAT TAACTGAGCA AGACACGGCT ATATTTCT

40 HIV-1 Env (Clade E)

1201 AGACGTCTTCTT ATCTGCTGCT TATTAATGTTA AGGACATGGG TTATGCTCT
TCTGAAAGA TCAAATGAC ATATAATACG ATATAACAT CCTGCTACG ATATGAGAA

45 HIV-1 Env (Clade E)

1261 GCGCTGGCTG AGCTTACGAT TCCGATACAT GGTGCTGCTG TCTGGCTG
CTGTCACGCG TGTAACTGCTA AGACGCTACG ATGGCTGCTG AGGACGCTACG AGGACGCTA

50 HIV-1 Env (Clade E)

1321 GTCATGGTTT AGACGTTGAT CCTGATACAT GGTGCTGCTG TCTGGCTG
CTGTCACGCG TGTAACTGCTA AGACGCTACG ATGGCTGCTG AGGACGCTACG AGGACGCTA

55 HIV-1 Env (Clade E)

1381 GTCATGGTTT CCTGATGCTA AGATTCGCTG TACATCTTCG AGGTGTAATT CCTGGCTGCT
CTATAAAGG CTGTCACGCTA TTAAAGAGCA ATGTTAAGGG TCGACGATTA GAGACGCTACG

60 HIV-1 Env (Clade E)

1441 GGGCTCTGCTG CCTGATGCTG CGACGCTACG TCGCTCTGCTG TCTGGCTG
CTGACGACAC CTATGCTGCTG CTACACAGG GTCCTCTAC AGGAAAGAC AGGAAACAC

65 HIV-1 Env (Clade E)

1501 TTGGCTCTCT CCTGATGCTA ATAGGCGCTG ATTCGCTACG CCTGGCTG
AAACGGTACA CTACGGCTGT TCTGGCTGCTA TACGCTGCTG GAGGCTGCTG CCTGGCTGCT

70 HIV-1 Env (Clade E)


1561 ATTAACGCTGTA AGGCAAGT TGTGCTGCTG ATTCGCTACG ATGGCTGCTG
TATTTGACAT TGGGGCTGCA AGACGCTACG TGTGCTGCTG TACGCTGCTG GTCCTCTAC

75 HIV-1 Env (Clade E)

1621 ATGGCCGCT TCTGACAGT TGTGCTGCTG TCTGGCTGCTG TCTGGCTG
CTACGGCTGTA AGGCTGCTG ATGGCTGCTG TACGCTGCTG AGGAGGCTG ATATACTGTA

1681 5' GCGAGCTCA CGGATATCGG GAACTGAGA TTAATTGAGG TTATTTGCGG CTTTCAGTC
TGTTGAACT GCGTATACCG CTATTATTTT ATTAAATACT ATAAAGAGAC GAAAGTTAA
5' 1741 5' AGACAGAGCG TCAAGAGACCT TTGTTATTTT TAACTTAAAGA ATAAAGAGAC
TTCTTCTGG AGTTCTTGA AGACAGAGCA AAAGTAAAGA ATTCAGCTT TTATTCGCG
5' 1801 10' 5' TCTAATTAACT TAAGCTTACAA ATACGTTTCTT TTCTACCTTC TCTAATTAACT ATATTAATTA
AGTTAACTT ATTCGAGCTT TCTCAGCA AAATGAGAC AGTTTATTC TTCTAATTAACT
13L Pr. 1861 15' 5' CGGGGCTCT GAGATAAGT GAAATATAT ATCACTATAG TAACTGAGAC AACTTTTCG
GGGGCTAGAG CTCCTATTTCA CTTTTATATA TAGTATATA ATGTTTCATG TTATAAATC
13L Pr.
HIV-1 gag/pro (IIIB)
1921 20' 5' GTTTATCCAT CGGTCGAGAG CGCTCACTAT TAACTGGGGC AGAAATTAATG CGGGGCGAA
CAAAATTAGA CTCACGCTCT CGGAGCTATA ATTCGGGGCG TCTCTATCTA GTCAGCTCTT
HIV-1 gag/pro (IIIB)
1981 25' 5' TAACTCCGT AGGGCGAGGG CGGAAAGAGA ATATTAATTTT TAACTATATA GTCGGCGAA
TTAAAGCCAA TTGGGGCTCC CGTTTCTTCTT TTATTTATATA TTCTTCTAT TCAACGCTCTT
HIV-1 gag/pro (IIIB)
2041 30' 5' KCGGGGAGCT AGAAAGAGTC CGAGCTTAAC CGGGCTCTT TGGAACTAA GAGCTGCTAA
CGGGGGCTCG TTTGGTAAAG CGGGGGCTAG GACGGGAA TCTTTGCTGT CGGGGGCGAT
HIV-1 gag/pro (IIIB)
2101 35' 5' GAAATATAC CGGACAGCTTC TTCTGGCTGG AGCTATGAGA TAAAGACAGCA
ATATTTATAG TCACTGGTTTCG GAGATAMTCG AGCTTCTTC CGATCTCTAT TTCTCTCTT
HIV-1 gag/pro (IIIB)
2161 40' 5' TATATAATAC AGGAGCTTC CGGGGGCTGG TGGCTCTAG GAGTGGATA TAAAGACAGCA
ATATTTATAG TCACTGGTTTCG GAGATAMTCG AGCTTCTTC CGATCTCTAT TTCTCTCTT
HIV-1 gag/pro (IIIB)
2221 45' 5' AGGGAGCTT AGGAGCTTC CGGGGGCTGG TGGCTCTAG GAGTGGATA TAAAGACAGCA
TCTGGAGA TCTGGCTCTG TTCTCTCTT TTCTCTCTT ATCTTTCTT CGGGGGCTCTG
HIV-1 gag/pro (IIIB)
2281 50' 5' CGGGGGCTCA CGGAGGAGAC AGGGGGCTTC TTCTCTCTG TGGCTCTAG
AGGGGGCTCTG TTCTCTCTG AGGGGGCTTC AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG
HIV-1 gag/pro (IIIB)
55' 5' TGGAGGAGAA CGGGGGCTTC AGGGGGCTTC TTCTCTCTG TGGCTCTAG
ATGGGGCTCTG TTCTCTCTG AGGGGGCTTC AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG
HIV-1 gag/pro (IIIB)
2341 60' 5' GAGGGGGCG AGGGGGCTTC AGGGGGCTTC TTCTCTCTG TGGCTCTAG
TTGGGGCTCTG TTCTCTCTG AGGGGGCTTC AGGGGGCTCTG AGGGGGCTCTG AGGGGGCTCTG
HIV-1 gag/pro (IIIB)
2381 65' 5' TGGGGGGCG CGGGGGCTTC CGGGGGCTTC AGGGGGCTTC AGGGGGCTCTG
AGGGGGCTTC AGGGGGCTTC AGGGGGCTTC AGGGGGCTTC AGGGGGCTTC AGGGGGCTCTG
HIV-1 gag/pro (IIIB)
2441 70' 5' GAGCTACTAG TACCTCTAG GAACTAATAG CGGGGGCTTC AGGGGGCTTC CGGGGGCTCTG
GAGCTACTAG TACCTCTAG GAACTAATAG CGGGGGCTTC AGGGGGCTTC CGGGGGCTCTG
HIV-1 gag/pro (IIIB)

		GGTGGATGTC ATTCGGAGCGC CTTTTTATTCG CTGGCTCTGT TTATTTAGGGT GCGATGGCGC HIV-1 gag/pro (IIIB)
5	2761	TAGGAGAAAT TTATTAAGAGA TGTGTTTATCC TTTGTTTTAA TAAATATGTC AGATATGTC ATGCGTTTA AATTTTTCGTC ACCCTTATTCG AGCGTATTTT ATTTCATTTT TGTGATGAT HIV-1 gag/pro (IIIB)
10	2761	GGCTTACCGG CATTGCGAC ATAGACAGAG GGGCAAGAG AGGCTTATGC GACTATGAG GGGGATGCTG CTAGACGCTG TATTGCTGC CTGGTTTCTG TGGAAATCTG CTGATGCTG HIV-1 gag/pro (IIIB)
15	2821	ACCGGTTCTA TAAACCTCTA AGAGCGCGCG AGGCTTCTCA GGAGCTTAAK ATTTCGTCG TGGGCAAAAT ATTTCGAGCTG TCGGGCTGCG TGGAGAGCTG CCTCCATTTT TTACGCTCT HIV-1 gag/pro (IIIB)
20	2861	CAGAAACCTT GTGGGGCGAG AATGCGAGC GAGTTTCTAA GACTATTTA AAAGCTTGG GTCTTTCGAA CAACAGCTG TTACGCTTG GCTTACATTT CGATAAAAT TTTCGTAAAC HIV-1 gag/pro (IIIB)
25	2941	GGCGCGCGG TACACTGAGA GAAATGAGA GAGCTTCA GAGATGAGA CGACCGCGC CTGGTGCCTG ATGGTGAATCT CTCCTCTCTG GCGTAAAGCTG CCTCTCTCTG CCTGGCTG HIV-1 gag/pro (IIIB)
30	3001	ATAAAGGAAAG ATTTTGCGT GAAAGCTGAG GCGAAATGAG GATTTGCGT ACCCTATGCA TATTCGCTTC TAAAGAGAGA CCTTGTCTCTG CTCCTCTTG TTAAATGAGA TGTGTTACT HIV-1 gag/pro (IIIB)
35	3061	TCGAAKAGG CATTTCAGG ATTCGAGAGA AGATTTTAA GGTGTTCTAT TTTCGGAAAG ACGCTCTCTG CCTTAAATGCT TTGTGTTCTG TCTACGCTT GCGAAATGTTT AGCGCTTGC HIV-1 gag/pro (IIIB)
40	3121	AAAGGACAGAG AGGAAAGAAAT TGTGGGGCGG CTGGGAAAGAG AGGCTGCTTG GAGTGTGAA TTCGCTCTG TCGGGCTCTA AGCGCGCGCG GATGCTTTTT CGCGGAGACCG TTTCGACCT HIV-1 gag/pro (IIIB)
45	3181	AGGAGAGACA CGAAATGAGA GATTTGACTG AGCGACAGCG AGATTTTTTA GGGAAAGCTG TCCCTCTCTG CGTTTACTTG CTAACTCTAG TGTGTTGCG AG TAAAGAAAG TCGTTCTAGA HIV-1 gag/pro (IIIB)
50	3241	GGCTTCCCTA CGGGGAGAG CGACGCTTCTT TTCTTCAGAG CAGACCGAG CGAACGGCG CGCGAAAGCTG GTTGGCTCTGCG AGTCAGCTTCG GCTGGCTCTG GCTTGTGCG HIV-1 gag/pro (IIIB)
55	3301	CACCAAGAGA GAGTTTCAGT TGTGTTGAG AGAGACAAAC TCCCTCTGAG AGAGCTTGGAG GGGGTCTCTGCTGCTGAGCTG AGAGCGCTCG TGTGTTGCTG AGGGGGAGTC TTGCTGCTGCG HIV-1 gag/pro (IIIB)
60	3361	GGATAGACAA CGAACTGCTG CCTTGTACCTG CGCTGAGAGC AGCTCTTGGCG AGCGCGCGCT GCTATGTGTT CCTTGACATA CGGAAATGAGA GAGAGCTGAG TGAAGAGACCG TTGGCTGGCGA HIV-1 gag/pro (IIIB)
65	3421	GGTGAGCTTA TAAAGAGGCG CGGAACTCTA AGAGCGCGCA TTAGGAGAGAG GAGGAGCTGA CGATGGTTAT TTGTATCGCG CGGGTTTCTG GCTTCGAGCT ATTCTATGTC CGCTGGCTCT TACACTTATTA CGAAAGATGCA CTTCGCGCG AGAGCTGAGA CGAAATATGAG TGTGTTCTG ATGTTTAAAT CGTTTCTGAG TAAAGCTGAG TGGGGCTCTG AGAGCTGAGT ATTCTTCTG TGGAGGCTTA ATCAAGCTGAG TACGAGCTGC AGCTGCGAG AGATTTTCTG TGTGTTCTG HIV-1 gag/pro (IIIB)
70	3481	GGTGGCTCTG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TACAGCTGAG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TGGAGGCTTA ATCAAGCTGAG TACGAGCTGC AGCTGCGAG AGATTTTCTG TGTGTTCTG HIV-1 gag/pro (IIIB)
75	3541	GGTGGCTCTG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TACAGCTGAG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TGGAGGCTTA ATCAAGCTGAG TACGAGCTGC AGCTGCGAG AGATTTTCTG TGTGTTCTG HIV-1 gag/pro (IIIB)
80	3601	GGTGGCTCTG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TACAGCTGAG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TGGAGGCTTA ATCAAGCTGAG TACGAGCTGC AGCTGCGAG AGATTTTCTG TGTGTTCTG HIV-1 gag/pro (IIIB)
85	3661	GGTGGCTCTG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TACAGCTGAG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT ATTCTTCTG TGGAGGCTTA ATCAAGCTGAG TACGAGCTGC AGCTGCGAG AGATTTTCTG TGTGTTCTG HIV-1 gag/pro (IIIB)
90	3721	ATGGTTTACG TACGAAATAG AGGAAAGAG AGTAAATGAG TAAATATGAG ATCTTATGAG TAACTTATGAG ATGAGTTTACG TGTGTTCTG AGAGCTGAGT ATTCTTCTGAG AGAGCTGAGT C6 Flanking seq
95	3781	GGGAAAGCGA AATGAG TTCCTCTGAG TGTGTTCTG

FIGURE 3

SEQUENCE LISTING

<110> Sanofi Pasteur Ltd.
 <120> Immunological Compositions
 <130> APL-09-03-PR

5 <160> 6

<170> PatentIn version 3.5
 <210> 1
 <211> 1478
 <212> DNA

10 <213> Human immunodeficiency virus

<400> 1

ggtacatgtg	tggaaagaag	caaccaccac	tctatttgt	gcacatcgatg	ctaaagcata	60
tgatatacagag	gcacataatg	tttggccac	acatgcgtgt	gtacccacag	accccaaccc	120
acaagaagta	gaattggtaa	atgtgacaga	aaattttaac	atgtggaaaa	ataacatggt	180
15 aeaacagatg	catgaggata	taatcagttt	atgggatcaa	agecttaaagc	catgtgttaa	240
attnaaccce	ctctgtgtta	ctttaaattt	cactgattt	aggaataacta	ctaataccaa	300
taatagtaact	gataataaca	atagtaaaag	cgagggaaca	ataaaggggag	gagaaatgaa	360
aaactgtctt	ttcaatatacc	ccacaagcat	aggagataag	atgcagaaag	aatatgcact	420
tctttataaa	cttgcataat	aaaccaataga	taatgatagt	accagctata	ggttgataag	480
20 ttgttaatacc	tcagtcatta	cacaagttt	tccaaagata	tctttgagc	caattccccat	540
acactattgt	ccccccggctg	gttttgcgt	tctaaagtgt	aacgataaaa	agtttcagtcgg	600
aaaaggatca	tgtaaaaatg	tcagcacagt	acaatgtcaa	catggaaat	gcgcagtagt	660
atcaactcaa	ctgtgtttaa	atggcagtct	agcagaagaa	gaggtatcaa	tttagatctga	720
ggatttcaat	gataatgcta	aaaccatcat	agtacatctg	aaagaatctg	tacaaattaa	780
25 ttgttcaaga	ccccactaca	ataaaaagaaa	aaggatacat	ataggaccag	ggagagcat	840
ttatacaaca	aaaaatataa	aaggaactat	aagacaagca	catgttatca	tttagtagagc	900
aaaatggaaat	gacactttaa	gacagatagt	tagcaagttt	aaaagaacaat	ttaagaataaa	960
ascaatagtc	tttaatccat	cctcaggagg	ggacccagaa	attgtatgc	acsgttttaa	1020
tttgtggaggg	gaatttttct	actgtatatac	atcaccactg	ttttaatagta	tttggaaatgg	1080
30 taataatact	tggaaataata	ctacagggtc	aaataacact	atccacacttc	atgcaaaaat	1140
aaaacaaatt	ataaacatgt	ggcagaaagt	aggaaaagca	atgtatgccc	ctcccatgt	1200
aggacaatatt	agatgttcat	caaataattac	agggctacta	ttaacaagag	atgggtggtga	1260
ggacacggac	acgaacgaca	ccgagatctt	cagacactgga	ggaggagata	tgagggacaa	1320
ttggagaatgt	gaatttatata	aatataaagt	agtaacaatt	gaaccaattag	gagtagcacc	1380
35 caccaaggca	aagagaagag	tggtgcagag	agaaaaaaaga	gcacgcgatag	gagctctgtt	1440
ccttgggttc	tttaggagcag	caggaaggcac	tatgggcg			1478

<210> 2

<211> 492
 <212> PRT
 <213> Human immunodeficiency virus
 <400> 2

5 Val Pro Val Trp Lys Glu Ala Thr Thr Leu Phe Cys Ala Ser Asp
 1 5 10 15
 Ala Lys Ala Tyr Asp Thr Glu Ala His Asn Val Trp Ala Thr His Ala
 20 25 30
 Cys Val Pro Thr Asp Pro Asn Pro Glu Glu Val Glu Leu Val Asn Val
 10 35 40 45
 Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met Val Glu Cln Met His
 30 35 40 45
 Glu Asp Ile Ile Ser Leu Trp Asp Cln Ser Leu Lys Pro Cys Val Lys
 45 50 55 60
 15 Leu Thr Pro Leu Cys Val Thr Leu Asn Cys Thr Asp Leu Arg Asn Thr
 50 55 60
 Thr Asn Thr Asn Asn Ser Thr Asp Asn Asn Asn Ser Lys Ser Glu Gly
 65 70 75 80
 Thr Ile Lys Gly Gly Glu Met Lys Asn Cys Ser Phe Asn Ile Thr Thr
 80 85 90 95
 20 Ser Ile Gly Asp Lys Met Cln Lys Glu Tyr Ala Leu Tyr Lys Leu
 95 100 105 110
 105 Asp Ile Glu Pro Ile Asp Asn Asp Ser Thr Ser Tyr Arg Leu Ile Ser
 115 120 125
 115 120 125
 25 Cys Asn Thr Ser Val Ile Thr Glu Ala Cys Pro Lys Ile Ser Phe Glu
 130 135 140
 130 135 140
 135 Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys
 145 150 155 160
 145 150 155 160
 145 150 155 160
 30 Cys Asn Asp Lys Lys Phe Ser Gly Lys Gly Ser Cys Lys Asn Val Ser
 160 165 170 175
 160 165 170 175
 165 Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys
 175 180 185 190
 175 180 185 190
 175 180 185 190
 180 Cys Asn Asp Lys Lys Phe Ser Gly Lys Gly Ser Cys Lys Asn Val Ser
 195 200 205
 195 200 205
 195 200 205
 210 Thr Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu
 215 220
 215 220
 215 220 225
 225 Leu Leu Asn Gly Ser Leu Ala Glu Glu Val Val Ile Arg Ser Glu
 230 235 240
 225 230 235 240
 230 235 240
 235 240
 235 240
 235 240
 245 Asp Phe Thr Asp Asn Ala Lys Thr Ile Ile Val His Leu Lys Glu Ser
 250 255 260
 245 250 255
 245 250 255
 245 250 255
 250 Val Gln Ile Asn Cys Thr Arg Pro Asn Tyr Asn Lys Arg Lys Arg Ile
 260 265 270
 250 255 260
 250 255 260
 250 255 260

His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Lys Gly
 275 280 285
 Thr Ile Arg Gln Ala His Cys Ile Ile Ser Arg Ala Lys Trp Asn Asp
 290 295 300
 5 Thr Leu Arg Gln Ile Val Ser Lys Leu Lys Glu Gln Phe Lys Asn Lys
 305 310 315 320
 Thr Ile Val Phe Asn Pro Ser Ser Gly Gly Asp Pro Glu Ile Val Met
 325 330 335
 His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Ser Pro
 10 340 345 350
 Leu Phe Asn Ser Ile Trp Asn Gly Asn Asn Thr Trp Asn Asn Thr Thr
 355 360 365
 Gly Ser Asn Asn Asn Ile Thr Leu Gln Cys Lys Ile Lys Gln Ile Ile
 370 375 380
 15 Asn Met Trp Gln Lys Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Glu
 385 390 395 400
 Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg
 405 410 415
 Asp Gly Gly Glu Asp Thr Asp Thr Asn Asp Thr Glu Ile Phe Arg Pro
 20 420 425 430
 Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr
 435 440 445
 Lys Val Val Thr Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys
 450 455 460
 25 Arg Arg Val Val Gln Arg Glu Lys Arg Ala Ala Ile Gly Ala Leu Phe
 465 470 475 480
 Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly
 485 490

 30 <210> 3
 <211> 472
 <212> PRT
 <213> Human immunodeficiency virus
 <400> 3

 35 Val Pro Val Trp Lys Glu Ala Asp Thr Thr Leu Phe Cys Ala Ser Asp
 1 5 10 15
 Ala Lys Ala His Glu Thr Glu Val His Asn Val Trp Ala Thr His Ala
 20 25 30

Cys Val Pro Thr Asp Pro Asn Pro Glu Glu Ile Asp Leu Glu Asn Val
 35 40 45
 Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met Val Glu Glu Met Glu
 50 55 60
 5 Glu Asp Val Ile Ser Leu Trp Asp Glu Ser Leu Lys Pro Cys Val Lys
 65 70 75 80
 Leu Thr Pro Pro Cys Val Thr Leu His Cys Thr Asn Ala Asn Leu Thr
 85 90 95
 Lys Ala Asn Leu Thr Asn Val Asn Asn Arg Thr Asn Val Ser Asn Ile
 10 100 105 110
 Ile Gly Asn Ile Thr Asp Glu Val Arg Asn Cys Ser Phe Asn Met Thr
 115 120 125
 Thr Glu Leu Arg Asp Lys Lys Glu Lys Val His Ala Leu Phe Tyr Lys
 130 135 140
 15 Leu Asp Ile Val Pro Ile Glu Asp Asn Asn Asp Ser Ser Glu Tyr Arg
 145 150 155 160
 Leu Ile Asn Cys Asn Thr Ser Val Ile Lys Glu Pro Cys Pro Lys Ile
 165 170 175
 Ser Phe Asp Pro Ile Pro Ile His Tyr Cys Thr Pro Ala Gly Tyr Ala
 20 180 185 190
 Ile Leu Lys Cys Asn Asp Lys Asn Phe Asn Gly Thr Gly Pro Cys Lys
 195 200 205
 Asn Val Ser Ser Val Glu Cys Thr His Gly Ile Lys Pro Val Val Ser
 210 215 220
 25 Thr Glu Leu Leu Asn Gly Ser Leu Ala Glu Glu Ile Ile Ile
 225 230 235 240
 Arg Ser Glu Asn Leu Thr Asn Asn Ala Lys Thr Ile Ile Val His Leu
 245 250 255
 Asn Lys Ser Val Val Ile Asn Cys Thr Arg Pro Ser Asn Asn Thr Arg
 30 260 265 270
 Thr Ser Ile Thr Ile Gly Pro Gly Glu Val Phe Tyr Arg Thr Gly Asp
 275 280 285
 Ile Ile Gly Asp Ile Arg Lys Ala Tyr Cys Glu Ile Asn Gly Thr Glu
 290 295 300
 35 Trp Asn Lys Ala Leu Lys Glu Val Thr Glu Lys Leu Lys Glu His Phe
 305 310 315 320
 Asn Asn Lys Pro Ile Ile Phe Glu Pro Pro Ser Gly Gly Asp Leu Glu
 325 330 335

Ile Thr Met His His Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn
 340 345 350
 Thr Thr Arg Leu Phe Asn Asn Thr Cys Ile Ala Asn Gly Thr Ile Glu
 355 360 365
 5 Gly Cys Asn Gly Asn Ile Thr Leu Pro Cys Lys Ile Lys Glu Ile Ile
 370 375 380
 Asn Met Trp Gln Gly Ala Gly Gln Ala Met Tyr Ala Pro Pro Ile Ser
 385 390 395 400
 Gly Thr Ile Asn Cys Val Ser Asn Ile Thr Gly Ile Leu Leu Thr Arg
 10 405 410 415
 Asp Gly Gly Ala Thr Asn Asn Thr Asn Asn Glu Thr Phe Arg Pro Gly
 420 425 430
 Gly Gly Asn Ile Lys Asp Asn Trp Arg Asn Glu Leu Tyr Lys Tyr Lys
 435 440 445
 15 Val Val Glu Ile Glu Pro Leu Gly Val Ala Pro Thr Arg Ala Lys Arg
 450 455 460
 Arg Val Val Glu Arg Glu Lys Arg
 465 470

20 <210> 4
 <211> 472
 <212> PRT
 <213> Human immunodeficiency virus
 <400> 4

25 Val Pro Val Trp Arg Asp Ala Asp Thr Thr Leu Phe Cys Ala Ser Asp
 1 5 10 15
 Ala Lys Ala His Glu Thr Glu Val His Asn Val Trp Ala Thr His Ala
 20 25 30
 Cys Val Pro Thr Asp Pro Asn Pro Glu Glu Ile Asp Leu Glu Asn Val
 30 35 40 45

Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met Val Glu Gln Met Gln
 50 55 60
 Glu Asp Val Ile Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys
 65 70 75 80

35 Leu Thr Pro Leu Cys Val Thr Leu His Cys Thr Asn Ala Asn Leu Thr
 85 90 95
 Lys Ala Asn Leu Thr Asn Val Asn Asn Arg Thr Asn Val Ser Asn Ile
 100 105 110

Ile Gly Asn Ile Thr Asp Glu Val Arg Asn Cys Ser Phe Asn Met Thr
 115 120 125
 Thr Glu Leu Arg Asp Lys Lys Gln Lys Val His Ala Leu Phe Tyr Lys
 130 135 140
 5 Leu Asp Ile Val Pro Ile Glu Asp Asn Asn Asp Ser Lys Tyr Arg
 145 150 155 160
 Leu Ile Asn Cys Asn Thr Ser Val Ile Lys Gln Ala Cys Pro Lys Ile
 165 170 175
 Ser Phe Asp Pro Ile Pro Ile His Tyr Cys Thr Pro Ala Gly Tyr Ala
 10 180 185 190
 Ile Leu Lys Cys Asn Asp Lys Asn Phe Asn Gly Thr Gly Pro Cys Lys
 195 200 205
 Asn Val Ser Ser Val Gln Cys Thr His Gly Ile Lys Pro Val Val Ser
 210 215 220
 15 Thr Gln Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Ile Ile Ile
 225 230 235 240
 Arg Ser Glu Asp Leu Thr Asn Asn Ala Lys Thr Ile Ile Val His Leu
 245 250 255
 Asn Lys Ser Val Val Ile Asn Cys Thr Arg Pro Ser Asn Asn Thr Arg
 20 260 265 270
 Thr Ser Ile Thr Ile Gly Pro Gly Gln Val Phe Tyr Arg Thr Gly Asp
 275 280 285
 Ile Ile Gly Asp Ile Arg Lys Ala Tyr Cys Glu Ile Asn Gly Thr Glu
 290 295 300
 25 Trp Asn Lys Ala Leu Lys Gln Val Thr Glu Lys Leu Lys Glu His Phe
 305 310 315 320
 Asn Asn Lys Pro Ile Ile Phe Gln Pro Pro Ser Gly Gly Asp Leu Glu
 325 330 335
 Ile Thr Met His His Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn
 30 340 345 350
 Thr Thr Arg Leu Phe Asn Asn Thr Cys Ile Ala Asn Gly Thr Ile Glu
 355 360 365
 Gly Cys Asn Gly Asn Ile Thr Leu Pro Cys Lys Ile Lys Gln Ile Ile
 370 375 380
 35 Asn Met Trp Gln Gly Ala Gly Gln Ala Met Tyr Ala Pro Pro Ile Ser
 385 390 395 400
 Gly Thr Ile Asn Cys Val Ser Asn Ile Thr Gly Ile Leu Leu Thr Arg
 405 410 415

Asp Gly Gly Ala Thr Asn Asn Thr Asn Asn Glu Thr Phe Arg Pro Gly
 420 425 430
 Gly Gly Asn Ile Lys Asp Asn Trp Arg Asn Glu Leu Tyr Lys Tyr Lys
 435 440 445
 5 Val Val Gln Ile Glu Pro Leu Gly Ala Ala Pro Thr Arg Ala Lys Arg
 450 455 460
 Arg Val Val Glu Arg Glu Lys Arg
 465 470

10

<210> 5
 <211> 3796
 <212> DNA
 <213> Artificial Sequence

15 <220>

<223> Human immunodeficiency virus

<400> 5

agtacaataa	aaagtattaa	ataaaaatac	ttacttacgaa	aaaaatgact	aattagat	60
aaaaaaccgg	ggttatccct	gcctaactct	atcactaca	gagagtacag	caaaaactat	120
20 tcttaaacct	accaaggctc	ctactatcat	tatgaataat	ctttttctc	tctccaccac	180
tottctttg	gcccgggtgg	gtgcattcc	tagtggtca	atttgtacta	ctttatattt	240
atataattca	tttctccaaat	tgcctttat	atttctctct	ccaggctcga	aggctctcggt	300
agtattattt	agaccaccaat	ctttgtcaa	tagtattct	gtaatattt	atacacaatt	360
aatttttcca	ctgtatggag	gagcatacat	tgcattgcct	gttcctgtcc	acatgtttat	420
25 aatttgcattt	atcttgcatg	gaagtatgt	agtgcattt	cacccctcca	gggtttcaatt	480
ttccatgcaa	gtattattaa	acagtctgt	tgtattgcaa	tagaagaatt	ccctcttaca	540
ataaaaatga	tgcattgtaa	tttcttagatc	tccctctgag	ggtgggtgaa	agatatttgt	600
cttattat	aagtgcattt	ttaattttt	agttaccttt	tttassactt	catbccat	660
tgttccat	atctcacaat	atgcatttct	tatatctct	attatgtctc	ctgttctgtt	720
30 gaatacttgt	cctggtccta	tatttatact	tgttctgtt	ttgttggagg	gtctggtaca	780
attgatttct	acagatttat	taaggtgcac	tattatggtt	ttggcattgt	tgtgagatt	840
ttcagatctg	attattatct	tttcttcgc	tagactgcca	tttaacagca	attgagttga	900
taccacaggc	ttaattccat	gtgtgcattt	tactgagctg	acattttac	atggccctgt	960
cccatggaa	ttctttatcat	tacactttaa	aatgcataaa	ccagctggag	tacaataat	1020
35 tataggaaatt	ggatcaagg	atatcttgg	acaaggctgc	ttaatgactg	asgtattaca	1080
atttattaaac	ctatactcac	tactacttgt	gttatcttca	attggacta	tatcaagctt	1140
gtagaatagt	gcattggacct	tctgcattt	atctcttagt	tctgtggtca	tataaaaga	1200
acagttttttt	acttcatctg	tatatttcc	tattatgtt	gggacattgg	tatgttctt	1260

5	gacattggtc acatttagcat tggtacaatt taaagtaacg cagagaggag ttaactttac acatggtttt agactttgtat cccataaaact gattacatcc tcctgcatct gctctaccat gttatttttc cacatgttaa aattttctgt tacatttcc aggtgttaatt cttgtgggtt ggggctgtgtg ggtacacagg catgtgtggc ccagacattg tgccgttctg tctttgtgc tttggcatct gatgcacaaa atagggtgtt atctgcatct ctccatacag gaacccata ataaaactgtt acccacaagt tgtctgagc actacaaatt atcaccaacc caaggatcaa agtccccat ttccacaagt ttggccaagt catctgtgtc tccttcactc tcattacgt acaaacttac cggatatacgc gataatgaaa taatttatgtt ttatttctcg ctttcaattt acacacaaccc tcaagacact ttgtatttt tttactttt taagtataga ataaagaagc tctaattaaat taagctacaa atagittcgt tttcacccctg tctaataact aattaattaa ccggatctt gagataaaagt gaaaatataat atcattataat tacaatgtac aattatTTAG gtttatcat ggggtgcgaga gcgtcagtat taaygggggg sgaatttagt cgatgggaaa aaattcgggt aaggccaggg ggaaaagaaaa aatataaatt aaaacatata gtatgggca gcagggagct agaacgattc gcagttaatc ctggcctgtt agaaacatca gaaggctgtt gacaaataact gggacagcta caaccatccc ttccagacagg atcagaagaa cttagatcat tstataatac agtagcaacc ctctattgtg tgcatcaaag gatagagata aaagacacca aggaagcttt agacaagata gaggaagagc aaaacaaaaag taagaaaaaa gcacagcaag cagcagctga cacaggacac agaatcagg tcagccaaaa ttacccctata gtgcagaaca ttcaggggca aatggtacat cagggccatata cacctagaac tttaaatgtca tgggtaaaag tagtagaaga gaaggtttc agcccagaag tgatccccat gttttcagca ttatcagaag gagccacccc acaagatita aacaccatgc taaacacagt ggggggacat caagcagcc tgcaaatgtt aaaagagacc atcaatgagg aagctgcaga atgggataga gtgcattccag tgcatgcagg gcctattgca ccaggccaga tgagagaacc aaggggaagt gacatagcag gaactactag tacccttcag gaacaaaatac gatggatgac aaataatccs octatcccg taggagaat ttataaaaaga tggataatcc tgggataaaa taaaatagtt agaatgtata gccttaccag ctttcgttgc ataaagacaag gacccaaaaga accctttaga gactatgttag acgggttcta taaaactcta agagccgagc aagttccaca ggaggtaaaa aatrggatgca cagaaacctt gttggccaa aatggaaacc cagattgtaa gacttttttta aagcattgg gaccagcggc tacactagaa gaaatgtatc cagcatgtca gggagtagga ggcacccggcc ataaggcaag agttttggct gaagcaatgc gccaagtaac aaattcagct accataatgc tgcaagagagg caatttttagg caccaaaagaa agattgttaa gtgtttcaat tggggcaaaag aagggcacac agccagaaat tgccaggccc ctggaaaaaa gggctgttgg aastgtggaa aggaaggaca cccaaatgaaa gattgtactc agagacaggg taatTTTTTaa gggaaagatct ggccttccta caagggaaagg ccaggaaatt ttcttcagag cagaccagag coacacggcc caccagaaga gagcttcagg tctgggytag agacaacaaac tccccctcag aagcaggagc cgatagacaa ggaactgtat ctttttaactt cccctcagatc actctttggc aacgacccct cgtcacaata aagatagggg ggcaactaaa ggaagctcta ttagatacag gagcagatgc tacatgttataa gaaatgtt gtttgcagg aagatggaaa cccaaaatgtt tagggggaaat 35	1320 1380 1440 1500 1560 1620 1680 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3420 3480 3540
---	--	--

tggagggtttt atcaaagtaa gacagtatga tcagatactc atagaatctt gtggacataa	3600
egctataaggc acagtatttag taggacctac acctgtcaac ataatcgaa gaaatctgtt	3660
gactcagatt ggttgcactt taaattttta acccgggtg cagtcgagg aattctttt	3720
attgattaac tagtcaaattg agtataatata attgaaaaag taaaatataa atcatataat	3780
5 aatgaasccgaa atatcc	3796

<210> 6	
<211> 3796	
10 <212> DNA	
<213> Artificial Sequence	
<220>	
<223> Human immunodeficiency virus	
<400> 6	
15 tcatgttatt ttccataatt tattttatg aatgaatgtt tttttactga ttaatccata	60
tttttggcc ccaataggaa cggatggaa taatgtatgt ctctcatgtc gtttttgata	120
agaattttgga tggttcggag gatgatagta atacttatta gaaaaaaagag agaggtggtg	180
agaagaasaaac cgcgcaccacc cccgataagg atcaccatgt taaacatgt gaaatataaa	240
tatattaagt gaaagaggtt aacaggaaata taaaggagga ggtccagact tccagagcaa	300
20 tcataataac tctggtggtt gagaacagt atcataagga cattataaac tatgtgtttaa	360
ttaagaaggt gactaccctc ctgtatgtt acgaacagga cggggacgg ttttacaaata	420
ttaaacgaaa tagaacgtac cttcataacta tcacggtaat gtggggaggt accaaatgtt	480
aaggtacgtt cataataatt tgcacgcaca acataacytt atcttcttaa ggggagatgt	540
taattttact acgttaacatt aaagatctag aggaggactc ccaccaactt tctataataaca	600
25 gaataataat ttccacgagaa aattaaaaaa tcacatggaaa aattttggaa gtaaggtaaa	660
acaaggtaat tagagtgtt aacgaaaaga atatagagga taatcacagag gacaagacat	720
cttacatgaaac ggaccaggat ataaatgtt acaagatcat aacaacccctcc cagaccatgt	780
taactaaaga tgtctaaata attccacgtt ataaatccaa aaccgttaaca aacactctaa	840
aagtcttagac taataataga gaagaagacg atctgacggtt aaattgttgt taactcaact	900
30 atggtgtccg aattaaaggta cacacgttaac atgactcgac tgtaaaaatg tccgggaca	960
gggttaacttt aagaatagtta atgtgaaatt ttagcgttatt ggtccacccctc aatgttattac	1020
atatccctaa cctagttcc tatagaaacc tggccggacg aatctactgac tccataatgt	1080
taaataattt gataatgttgtt atgatgagca caatagaatgt taacccatgt atagttcgaa	1140
catcttataca cgtacctggaa agacgaagaa tagagaatca agacaccagt ataaatttct	1200
35 tgtcaaagaa tgaagtagac aatataaagg ataaatacaat ccctgttaacc atacaagaa	1260
ctgttaaccatg tggtaatcgta accatgtttaa atttcattgc gtctctccctc aatgtaaatgt	1320
tgtaccaaaa tctgaaacta gggattttga ctaatgttagg aggacgtaga cggatgttca	1380
caataaaaaag gtgtacaatt ttaaaaagaca atgtaaaaagc tccacattaa gaacacccaa	1440

taactaattg atcagtttac tcatatata taacttttc attttatatt tagtatatta 3780
ttactttgtt ttatacg 3796

<210> 7

5 <211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Herpes simplex virus 1

10 <400> 7

Asp Tyr Ala Leu Ala Asp Ala Ser Leu Lys Met Ala Asp Pro Asn

5

10

15

Arg Phe Arg Gly Lys Asp Leu Pro Val Leu Asp Glu Leu

15 20 25